Document:

EX-4.4

Exhibit 4.4

NOTICE OF ANNUAL AND SPECIAL MEETING

OF SHAREHOLDERS TO BE HELD ON

THURSDAY, MARCH 25, 2010

AND

MANAGEMENT PROXY CIRCULAR

FEBRUARY 23, 2010

 

 

 

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

 

To the shareholders of Theratechnologies Inc. (the “Company”):

NOTICE IS HEREBY GIVEN that an annual and special meeting of shareholders (the “Meeting”) of the
Company will be held at the Centre Mont-Royal, 2200 Mansfield, Salon International, Montreal,
Québec, on Thursday, March 25, 2010 at 10:00 a.m., local time, for the following purposes:

	 	(1)	 	to receive the consolidated financial statements for the fiscal year ended
November 30, 2009, as well as the auditors’ report thereon;
	 
	 	(2)	 	to elect directors for the ensuing year;
	 
	 	(3)	 	to appoint auditors for the ensuing year and authorize the directors to set
their compensation;
	 
	 	(4)	 	to consider, and if deemed advisable, to pass Resolution 2010-1 (the text of
which is attached as Appendix A to the accompanying Management Proxy Circular), with or
without amendments, approving the shareholder rights plan, the whole as described in
the accompanying Management Proxy Circular; and
	 
	 	(5)	 	to transact such other business as may properly come before the Meeting.

DATED at Montreal, Québec, Canada, February 23, 2010.

	 	 	 

	 

	 	BY ORDER OF THE BOARD OF DIRECTORS
	 
	 	 
	 

	 	Jocelyn Lafond
	 

	 	Corporate Secretary

 

 

 

MANAGEMENT PROXY CIRCULAR

 

The information contained in this management proxy circular (the “Circular”) is given as at
February 23, 2010, except as otherwise noted. All dollar amounts set forth herein are expressed in
Canadian dollars and the symbol “$” refers to the Canadian dollar, unless otherwise indicated.

 

 

TABLE OF CONTENTS

	 	 	 	 	 

	ITEM I. INFORMATION RELATING TO THE ANNUAL AND SPECIAL MEETING
	 	 	1	 
	1. Voting
	 	 	1	 
	A. By Proxy
	 	 	1	 
	B. In Person
	 	 	2	 
	C. Voting Securities and Principal Holders
	 	 	2	 
	2. Subjects To Be Treated at the Meeting
	 	 	3	 
	A. Receipt of Financial Statements
	 	 	3	 
	B. Election of Directors
	 	 	3	 
	C. Appointment of Auditors
	 	 	5	 
	D. Approval of Shareholder Rights Plan
	 	 	6	 
	E. Other Matters to be Acted Upon
	 	 	10	 
	ITEM II. COMPENSATION
	 	 	11	 
	1. Executive Compensation
	 	 	11	 
	A. Compensation Discussion & Analysis
	 	 	11	 
	B. Summary Compensation Table
	 	 	15	 
	C. Incentive Plan Awards
	 	 	17	 
	D. Termination and Change of Control Provisions
	 	 	19	 
	E. Performance Graph
	 	 	24	 
	F. Other Information
	 	 	25	 
	2. Director Compensation
	 	 	26	 
	A. Determination of Director Compensation
	 	 	26	 
	B. Director Compensation Table
	 	 	27	 
	C. Incentive Plan Awards
	 	 	28	 
	D. Other Information
	 	 	31	 
	ITEM III. CORPORATE GOVERNANCE DISCLOSURE
	 	 	32	 
	1. Board of Directors
	 	 	32	 
	A. Independence
	 	 	32	 
	B. Meetings of the Board
	 	 	32	 
	C. Other Board Memberships
	 	 	33	 
	2. Mandate of the Board of Directors
	 	 	33	 
	3. Position Descriptions
	 	 	33	 
	4. Orientation and Continuing Education
	 	 	33	 
	5. Ethical Business Conduct
	 	 	34	 
	6. Nomination of Directors
	 	 	34	 
	7. Compensation
	 	 	34	 
	A. Independence
	 	 	34	 
	B. Meetings of the Compensation Committee
	 	 	34	 
	8. Audit Committee
	 	 	34	 
	A. Independence
	 	 	34	 
	B. Meetings of the Audit Committee
	 	 	35	 
	9. Other Committees
	 	 	35	 
	A. Financing Committee
	 	 	35	 
	B. Strategic Committee
	 	 	35	 
	10. Assessment
	 	 	36	 
	ITEM IV. OTHER INFORMATION
	 	 	37	 
	1. Additional Documentation
	 	 	37	 
	2. Approval By The Board Of Directors
	 	 	37	 
	APPENDIX A — Resolution 2010-1 Shareholder Rights Plan
	 	 	 	 
	APPENDIX B — Compensation Committee Charter
	 	 	 	 
	APPENDIX C — Mandate of the Board of Directors
	 	 	 	 
	APPENDIX D — Director Orientation and Continuing Education Policy
	 	 	 	 
	APPENDIX E — Nominating and Corporate Governance Committee Charter
	 	 	 	 

 

 

ITEM I. INFORMATION RELATING TO THE ANNUAL AND SPECIAL MEETING

1. Voting

You may vote your shares either through a proxy or in person at the annual and special meeting of
shareholders of the Company (the “Meeting”).

A. By Proxy

Solicitation of Proxies

This Circular is furnished in connection with the solicitation by the management of
Theratechnologies Inc. (the “Company” or “Theratechnologies”) of proxies to be used at the Meeting
of the Company to be held on Thursday, March 25, 2010, at the time, place and for the purposes set
forth in the attached Notice of Annual and Special Meeting of Shareholders (the “Notice of
Meeting”) and at any continuation of the Meeting after adjournment thereof.

The solicitation of proxies is being primarily made by mail but proxies may also be solicited by
telephone, telecopier or other personal contact by officers or other employees of the Company.
The entire cost of the solicitation will be borne by the Company.

Terms of Proxy Grant

By completing the enclosed form of proxy, or the one provided by your intermediary, you appoint the
persons proposed in that form to represent your interests and vote your shares on your behalf at
the Meeting. The persons named in the enclosed form of proxy are directors or officers of the
Company. However, you have the right to appoint a person or company other than the ones designated
in the form of proxy to represent you at the Meeting. To do this, you must insert such person’s
name in the blank space provided in the form of proxy enclosed hereto or complete another form of
proxy. It is not necessary to be a shareholder of the Company in order to act as a proxy.

If you hold your shares through an intermediary (a stockbroker, a bank, a trust, a trustee, etc.),
you are not a registered shareholder in the registry of shareholders of the Company held by
Computershare Trust Company of Canada (“Computershare”). Therefore, you cannot vote your shares
directly at the Meeting. If this is your situation, you will receive from your intermediary
explanation as to how to appoint proxies and have them vote your shares. To ensure that your
instructions are respected, you must deliver them to your intermediary within the prescribed
deadline. For any questions, please contact your intermediary directly.

Proxy Voting

The persons named or appointed in the form of proxy will, on a show of hands or any ballot that may
be called, vote (or withhold from voting) your shares in respect of which they are appointed as
proxies in accordance with the instructions given in the form of proxy. In the absence of
instructions, the voting rights attached to the shares referred to in your form of proxy will be
exercised FOR the matters mentioned in the attached Notice of Meeting.

Furthermore, the enclosed form of proxy confers upon the proxy holder a discretionary power with
respect to amendments or variations to matters identified in the Notice of Meeting and with respect
to all other matters which may properly come before the Meeting, or any continuation after
adjournment thereof.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 1
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

However, to our knowledge, all matters to be brought before the Meeting are mentioned in
appropriate fashion in the Notice of Meeting.

Delivery of Form of Proxy and Deadlines

If you hold your shares personally and are a registered shareholder in the registry of shareholders
of the Company, please send the completed form of proxy to the Secretary of the Company, c/o
Computershare Trust Company of Canada, 1100 University Street, 12th Floor, Montreal,
Québec H3B 2G7, prior to 5:00 p.m. (Eastern time) on March 23, 2010 (unless you attend the Meeting
in person). All shares represented by proper proxies accompanied by duly completed declarations
received by Computershare at the latest on such date and prior to such time will be voted in
accordance with your instructions as specified in the proxy form on any ballot that may be called
at the Meeting.

If you hold your shares through an intermediary, please proceed as indicated in the documentation
sent by your intermediary and within the deadlines specified therein. For any questions, please
contact your intermediary directly.

Revocation of a Proxy

You may, at any time, including any continuation of the Meeting after adjournment thereof, revoke a
proxy for any business with respect to which said proxy confers a vote that has not already been
cast.

If you hold your shares personally and are a registered shareholder in the registry of shareholders
of the Company, please send a written notice to revoke a proxy bearing your signature or that of
your proxy (or a representative of your proxy if your proxy is a company) to the Secretary of the
Company, c/o Computershare Trust Company of Canada, 1100 University Street, 12th Floor,
Montreal, Québec H3B 2G7, prior to 5:00 p.m. (Eastern time) on March 23, 2010. You may also revoke
a proxy in person at the Meeting by making a request to that effect to the Secretary of the
Company.

If you hold your shares through an intermediary, please proceed as indicated in the documentation
sent by your intermediary and within the deadlines specified therein. For any questions, please
contact your intermediary directly.

B. In Person

If you hold your shares personally and are a registered shareholder in the registry of shareholders
of the Company, you may present yourself on the date, at the time and place set forth in the Notice
of Meeting and register with the representatives of Computershare who will be at the Meeting. You
should then follow voting instructions given by the Chairman of the Meeting.

If you hold your shares through an intermediary and you wish to vote your shares in person at the
Meeting, please proceed as indicated in the documentation sent by your intermediary. For any
questions, please contact your intermediary directly.

C. Voting Securities and Principal Holders

As at February 22, 2010, there were 60,449,891 common shares (the “Common Shares”) of the Company
issued and outstanding. The Common Shares are the only securities with respect to which a voting
right may be exercised at the Meeting. Each Common Share entitles its holder to one vote with
respect to the matters voted on at the Meeting.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 2
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

Holders of Common Shares whose names are registered on the lists of shareholders of the
Company as at 5:00 p.m. (Eastern time) on February 22, 2010, being the date fixed by the Company
for determination of the registered holders of Common Shares who are entitled to receive notice of
the Meeting (the “Record Date”), will be entitled to exercise their voting rights attached to the
Common Shares in respect of which they are so registered at the Meeting, or any continuation after
adjournment thereof, if present or represented by proxy thereat. However, even if you have acquired
Common Shares after the Record Date, you will be entitled to vote at the Meeting if, at least
twenty-four (24) hours prior to the Meeting, you produce certificates for such Common Shares
properly endorsed by the seller, or if you otherwise establish that you own such Common Shares and
have requested that your name be included on the list of shareholders entitled to receive the
Notice of Meeting.

To our knowledge, no person beneficially owns, or controls or directs control, directly or
indirectly, over more than ten percent (10%) of the outstanding Common Shares of the Company.

2. Subjects To Be Treated at the Meeting

Please find below a description of the items listed in the Notice of Meeting.

A. Receipt of Financial Statements

The consolidated financial statements for the fiscal year ended November 30, 2009 together with the
auditors’ report thereon will be presented at the Meeting. The financial statements are included in
the Company’s 2009 annual report, which has been mailed to you if you requested it, along with this
Circular. The financial statements are also available on SEDAR at www.sedar.com. No vote is
required on this matter.

B. Election of Directors

The shareholders at the Meeting will appoint the directors of the Company for the coming year.

Composition of the Board of Directors

The articles of the Company provide that the board of directors of the Company (the “Board of
Directors”) must consist of a minimum of three (3) and a maximum of twenty (20) directors. The
Board of Directors has established that a number of nine (9) directors was well adapted to its size
and activities.

Nominees

All of the nominees for the director positions of the Company are elected for a one year term
ending at the next annual meeting of shareholders or when his successor is elected, unless he
resigns or the position becomes vacant as a result of death, dismissal or otherwise, prior to the
said meeting. We do not contemplate that any of the nominees will be unable to fulfill his mandate
as director. Unless instructions are given to abstain from voting with regard to the election of
directors, the persons whose names appear on the enclosed form of proxy will vote FOR the election
of the nominees whose names are set out in the table below.

At the Meeting, shareholders are asked to vote on a slate of directors. However, at a meeting of
the Nominating and Corporate Governance Committee held in December 2009, the members of this
committee agreed to review the election mode of directors for the next annual meeting of the
Company. The members of the committee will examine the opportunity to move from a bundled slate of
directors to an election of directors on an individual basis.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 3
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

The following table states the names of all persons proposed for election as directors, their
province or state and country of residence, their principal occupation, the position held in the
Company (if any), the year in which they first became directors of the Company and the number of
Common Shares they own, directly or indirectly, or over which they exercise control or direction.
To obtain additional information regarding the biographical notes of the nominees, shareholders can
consult item 4.1 of the Company’s 2009 annual information form dated February 23, 2010 available on
SEDAR at www.sedar.com.

The information relating to the number of Common Shares held by the nominees in the table below and
under “Cease Trade Orders, Bankruptcies, Penalties or Sanctions” is based on the statements made by
the nominees.

	 	 	 	 	 	 	 
	 	 	 	 	 	 	Number of Common
	 	 	 	 	 	 	Shares of the Company
	 	 	 	 	 	 	Owned, Directly or
	 	 	 	 	 	 	Indirectly,
	 	 	 	 	 	 	or Over Which
	Name, Province or State	 	 	 	Director	 	Control or
	and Country of Residence	 	Principal Occupation	 	Since	 	Direction is Exercised
	Paul Pommier(1) (2) (3) (4) (5)
	 	Chairman of the Board of the	 	 	 	 
	Québec, Canada
	 	Company	 	1997	 	190,100
	 
	 	 	 	 	 	 
	Gilles Cloutier(3) (5)

North Carolina, 

United States
	 	Corporate Director	 	2003	 	51,000
	 
	 	 	 	 	 	 
	A. Jean de Grandpré(2) (3) (4) (5)

Québec, Canada
	 	Corporate Director	 	1993	 	200,000
	 
	 	 	 	 	 	 
	Robert G. Goyer(3)
	 	Emeritus Professor	 	 	 	 
	Québec, Canada
	 	Faculty of Pharmacy	 	 	 	 
	 	 	Université de Montreal	 	2005	 	10,000
	 
	 	 	 	 	 	 
	Gérald A. Lacoste(1) (3) (5)

Québec, Canada
	 	Corporate Director	 	2006	 	11,000
	 
	 	 	 	 	 	 
	Bernard Reculeau(2)

Paris, France
	 	Corporate Director	 	2005	 	18,100
	 
	 	 	 	 	 	 
	Yves Rosconi(4)
	 	President and Chief Executive	 	 	 	 
	Québec, Canada
	 	Officer of the Company	 	2004	 	67,093
	 
	 	 	 	 	 	 
	Jean-Denis Talon(1) (2)
	 	Chairman of the Board	 	 	 	 
	Québec, Canada
	 	AXA Canada	 	 	 	 
	 	 	(Insurance Company)	 	2001	 	60,000
	 
	 	 	 	 	 	 
	Luc Tanguay(4)
	 	Senior Executive Vice President	 	 	 	 
	Québec, Canada
	 	and Chief Financial Officer of	 	 	 	 
	 	 	the Company	 	1993	 	83,000

 

			
	(1)	 	Member of the Audit Committee
	 
	(2)	 	Member of the Compensation Committee
	 
	(3)	 	Member of the Nominating and Corporate Governance Committee
	 
	(4)	 	Member of the Financing Committee
	 
	(5)	 	Member of the Strategic Review Committee

			
	 	 	 
	Information Relating to the Meeting
	 	Page 4
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

Cease Trade Orders, Bankruptcies, Penalties or Sanctions

Except as described below, to the knowledge of management of the Company, no nominee (a) is, as at
the date of the Circular, or has been within the ten (10) years before the date of the Circular, a
director or executive officer of any company (including the Company) that, while that person was
acting in that capacity, (i) was the subject of a cease trade or similar order or an order that
denied the relevant company access to any exemption under securities legislation, for a period of
more than thirty consecutive days; (ii) was subject to an event that resulted, after the director
or executive officer ceased to be a director or executive officer, in the company being the subject
of a cease trade or similar order or an order that denied the relevant company access to any
exemption under securities legislation, for a period of more than thirty consecutive days; or (iii)
within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal
under any legislation relating to bankruptcy or insolvency or was subject to or instituted any
proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or
trustee appointed to hold its assets; or (b) has, within the ten (10) years before the date of the
Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or
insolvency, or become subject to or instituted any proceedings, arrangement or compromise with
creditors, or had a receiver, receiver manager or trustee appointed to hold his assets.

Paul Pommier was a member of the board of directors of Royal Aviation Inc. from September 1996
until it was acquired by Canada 3000 Inc. in March 2001. Subsequently, at the end of 2001, Canada
3000 Inc. and its subsidiaries, including Royal Aviation Inc., made assignments in bankruptcy under
Section 49 of the Bankruptcy and Insolvency Act (R.S. 1985, c. B-3) (the “Bankruptcy Act”).

Yves Rosconi was a member of the board of directors of Mistral Pharma Inc. from September 2007
until May 2008. On June 13, 2008, Mistral Pharma Inc. filed a notice of intention to make a
proposal to its creditors under the Bankruptcy Act and, on August 19, 2008, Mistral Pharma Inc.
filed a proposal under the Bankruptcy Act.

Luc Tanguay is currently a member of the board of directors of Ambrilia Biopharma Inc. (hereafter
“Ambrilia”) and has been a member since August 22, 2006. On July 31, 2009, Ambrilia obtained court
protection from its creditors under the Companies’ Creditors Arrangement Act (Canada). The purpose
of the order issued by the court granting Ambrilia protection from its creditors is to provide
Ambrilia and its subsidiaries the opportunity to restructure its affairs. Ambrilia is still under
court protection. In addition, on July 31, 2009, the Toronto Stock Exchange halted the trading of
Ambrilia’s shares pending its review of Ambrilia’s meeting the requirements for continuous listing.
On August 5, 2009, Ambrilia announced that its shares would resume trading.

C. Appointment of Auditors

The Company’s auditors for the current fiscal year must be appointed at the Meeting. We propose the
appointment of KPMG LLP, chartered accountants from Montréal, who have been the Company’s auditors
since October 19, 1993. They will hold office until the next annual meeting of shareholders or
until their successors are appointed.

The table below sets forth the fees paid to the auditors of the Company for the financial years
ended November 30, 2009 and November 30, 2008.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 5
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

	 	 	 	 	 	 	 	 	 
	 	 	Financial Year Ended	 	 	Financial Year Ended	 
	 	 	November 30, 2009	 	 	November 30, 2008	 
	Audit Fees
	 	$	80,000	 	 	$	77,000	 
	Audit-Related Fees (1)
	 	$	17,500	 	 	$	71,300	 
	Tax Fees (2)
	 	$	39,626	 	 	$	40,064	 
	All Other Fees
	 	 	—	 	 	 	—	 

 

			
	(1)	 	Audit-related fees relate principally to services rendered in connection with the Company’s
quarterly financial statements. For the financial year ended November 30, 2008, audit-related
fees paid to KPMG also included fees related to services rendered in connection with the
Company’s public offering.
	 
	(2)	 	Tax fees relate to services rendered in connection with the preparation of corporate tax
returns and general tax advice.

Unless instructions are given to abstain from voting with regard to the appointment of
auditors, the persons whose names appear on the enclosed form of proxy will vote FOR the
appointment of KPMG LLP, chartered accountants, as auditors of the Company, and authorize that
compensation for their services be determined by the Board of Directors.

D. Approval of Shareholder Rights Plan

On February 10, 2010, the Board of Directors implemented a shareholder rights plan (the “Rights
Plan”), the terms and conditions of which are set out in a shareholder rights plan agreement (the
“Rights Agreement”) dated February 10, 2010 with Computershare Trust Services of Canada, as rights
agent. The Rights Plan is currently effective but is subject to approval by a majority of the votes
cast by shareholders, in person or by proxy, at the Meeting. If shareholders of the Company do not
approve the Rights Plan, it will cease to be effective and will terminate.

Purpose of the Rights Plan

The purpose of the Rights Plan is to ensure equal treatment of shareholders and to give adequate
time for shareholders to properly assess the merits of a bid without undue pressure, and to allow
competing bids to emerge. The Rights Plan is designed to give the Board of Directors time to
consider alternatives, allowing shareholders to receive full and fair value for their shares. The
Rights Plan was not adopted by the Board of Directors in response to any acquisition proposal and
is not designed to secure the continuance in office of the current management or the directors of
the Company. The adoption of the Rights Plan does not in any way lessen the duties of the directors
to fully and fairly examine all bids which may be made to acquire the Common Shares of the Company
and to exercise such duties with a view to the best interest of the shareholders and the Company.

Before deciding to adopt the Rights Plan, the Board of Directors considered the current
shareholdings of the Company and the legislative framework in Canada governing takeover bids. To
our knowledge, there is currently no person who beneficially owns, or controls or directs control,
directly or indirectly, over more than ten percent (10%) of the outstanding Common Shares of the
Company. Therefore, a person could acquire a de facto control of the Company through the purchase
of a number of Common Shares that would represent a percentage of Common Shares below 50% by
entering into private acquisition agreements without having to make an offer to all of the
shareholders.

Under provincial securities legislation, a takeover bid generally means an offer to acquire voting
or equity voting shares of a corporation that, together with shares already owned by the bidder and
certain parties related thereto, amount to 20% or more of the outstanding shares of that class.

The existing legislative framework for takeover bids in Canada presents the following concerns for
shareholders:

			
	 	 	 
	Information Relating to the Meeting
	 	Page 6
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

	1.	 	Time
	 
	 	 	Current legislation permits a takeover bid to expire 35 days after it is initiated. The Board
of Directors is of the view that this is not sufficient time to permit shareholders to
adequately consider a takeover bid and make a reasoned and unhurried decision.
	 
	2.	 	Pressure to Tender
	 
	 	 	A shareholder may feel compelled to tender his Common Shares pursuant to a takeover bid which
he considers to be inadequate, out of a concern that in failing to do so, the shareholder may
be left with illiquid or minority discounted Common Shares. The Rights Plan provides
shareholders with a mechanism which is intended to ensure that they can separate the decision
to tender, based on the merits of a bid, from the approval or disapproval of a particular
takeover bid.
	 
	3.	 	Unequal Treatment
	 
	 	 	Shareholders may not be treated equally if, as current securities legislation provides, an
important number of Common Shares is acquired pursuant to a private agreement in which a
small group of shareholders or a shareholder disposes of its Common Shares at a premium to
market price, which premium is not shared with the other shareholders of the Company. In
addition, a person may gradually accumulate Common Shares through stock exchange acquisitions
which results in an acquisition of control of the Company, without payment of fair value for
control or a fair sharing of a control premium amongst all shareholders. The Rights Plan
addresses these concerns by applying to all acquisitions of 20% or more of the Common Shares
of the Company, ensuring that shareholders receive equal treatment.

The issue of rights (the “Rights”) will not in any way adversely alter the financial condition of
the Company and will not change the way in which shareholders trade their Common Shares. However,
by permitting holders of Rights other than an “Acquiring Person” (as defined below) to acquire
additional Common Shares of the Company at a discount to market value, the Rights may cause
substantial dilution to a person or group that acquires 20% or more of the outstanding Common
Shares other than by way of a “Permitted Bid” (as defined below). A potential bidder can avoid the
dilutive features of the Rights Plan by making a bid that conforms to the requirements of a
Permitted Bid.

The Company has reviewed the Rights Plan for conformity with current practices of Canadian
companies with respect to shareholder protection rights plans. We believe that the Rights Plan
preserves the fair treatment of shareholders, is consistent with best Canadian corporate practices
and addresses institutional investor guidelines.

Terms of the Rights Plan

The following is a summary of the principal terms of the Rights Agreement and is provided subject
to the terms and conditions thereof. A complete copy of the Rights Agreement has been filed and is
available on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

Issue of Rights

In order to implement the Rights Plan, the Board of Directors authorized the Company to issue one
right in respect of each Common Share outstanding as of 6:00 p.m. (Montreal time) on February 9,
2010 (the “Effective Date”). One Right will also be issued and attached to each subsequently issued
Common Share.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 7
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

Rights-Exercise Privilege

The Rights will be separate from the Common Shares to which they are attached and will become
exercisable at the time (the “Separation Time”) that is ten (10) business days after the earlier
of: (i) the first date of public announcement that an “Acquiring Person” (as defined below) has
become such; (ii) the date of commencement of, or first public announcement in respect of, a
takeover bid which will permit an offeror to hold 20% or more of the Common Shares, other than by
an acquisition pursuant to a takeover bid permitted by the Rights Plan (a “Permitted Bid” as
defined below); (iii) the date upon which a Permitted Bid ceases to be a Permitted Bid; or (iv)
such other date as may be determined in good faith by the Board of Directors.

The acquisition permitting a person (an “Acquiring Person”), including others acting jointly or in
concert with such person, to hold 20% or more of the outstanding Common Shares, other than by way
of a Permitted Bid, is referred to as a “Flip-in Event.” Any Rights held by an Acquiring Person on
or after the earlier of the Separation Time or the first date of a public announcement (the “Common
Share Acquisition Date”) by the Company or an Acquiring Person that an Acquiring Person has become
such will become null and void upon the occurrence of a Flip-in Event. Ten (10) trading days after
the occurrence of the Common Share Acquisition Date, each Right (other than those held by the
Acquiring Person) will permit the holder to purchase for the exercise price that number of Common
Shares determined as follows: a value of twice the exercise price divided by the average weighted
market price for the last 20 trading days preceding the Common Share Acquisition Date. The exercise
price is currently $25 per Right, subject to adjustment provisions described in the Rights Plan.

Upon the occurrence of a Flip-in Event and the separation of the Rights from the Common Shares,
reported earnings per share on a fully diluted or non-diluted basis may be affected. Holders of
Rights who do not exercise their Rights upon the occurrence of a Flip-in Event may suffer
substantial dilution.

Lock-Up Agreements

A bidder may enter into lock-up agreements with the shareholders of the Company whereby such
shareholders agree to tender their Common Shares to the takeover bid (the “Lock-up Bid”) without a
Flip-in Event occurring. Any such agreement must permit or must have the effect to permit the
shareholder to withdraw the Common Shares to tender to another takeover bid or to support another
transaction that exceeds the value of the Lock-up Bid.

Certificates and Transferability

Prior to the Separation Time, the Rights will be evidenced by a legend imprinted on certificates
for Common Shares issued after the Effective Date. Rights are also attached to Common Shares
outstanding on the Effective Date, although share certificates will not bear such a legend. Prior
to the Separation Time, Rights will not be transferable separately from the Common Shares. From
and after the Separation Time, the Rights will be evidenced by Rights certificates, which will be
transferable and traded separately from the Common Shares.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 8
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

“Permitted Bid” Requirements

A “Permitted Bid” is a takeover bid that does not trigger the exercise of Rights. A “Permitted
Bid” is a bid that aims to acquire shares which, together with the other securities beneficially
owned by the bidder, represent not less than 20% of the outstanding Common Shares, which bid is
made by means of a takeover bid circular and satisfies the following requirements:

	(i)	 	the bid must be made to all holders of Common Shares;
	 
	(ii)	 	the bid must include a condition without reservation providing that no share
tendered pursuant to the bid will be taken up prior to the expiry of a period of not less than
60 days and only if at such date more than 50% in aggregate of the outstanding shares held by
the shareholders other than the bidder, its associates and affiliates, and persons acting
jointly or in concert with such persons (the “Independent Shareholders”), have been tendered
pursuant to the bid and not withdrawn;
	 
	(iii)	 	if more than 50% in aggregate of the shares held by Independent Shareholders are
tendered to the bid within the 60-day period, the bidder must make a public announcement of
that fact and the bid must remain open for deposits of shares for an additional ten (10)
business days from the date of such public announcement.

Waiver and Redemptions

The Board of Directors acting in good faith may, prior to a Flip-in Event, waive the dilutive
effects of the Rights Plan in respect of a particular Flip-in Event that would result from a
takeover bid made by way of takeover bid circular to all holders of Common Shares, in which event
such waiver would be deemed also to be a waiver in respect of any other Flip-in Event. The Board
of Directors may also waive the Rights Plan in respect of a particular Flip-in Event that has
occurred through inadvertence, provided that the Acquiring Person that inadvertently triggered
such Flip-in Event reduces its beneficial holdings to less than 20% of the outstanding Common
Shares within 14 days or any other period that may be specified by the Board of Directors. At any
time prior to the occurrence of a Flip-in Event, the Board of Directors may, subject to the prior
approval of the holders of Common Shares, elect to redeem all, but not less than all, of the
outstanding Rights at a price of $0.0001 per right.

Exemption for Investment Managers

Investment managers (for client accounts), trust companies and pension funds (acting in their
capacity as trustees and administrators) acquiring shares permitting them to hold 20% or more of
the Common Shares are exempt from triggering a Flip-in Event, provided that they are not making,
or are not part of a group making, a takeover bid.

Supplements and Amendments

The Company is authorized to make amendments to the Rights Plan to correct any clerical or
typographical error or to maintain the validity of the Rights Plan as a result of changes in laws
or regulations. Prior to the Meeting, the Company is authorized to amend or supplement the Rights
Plan as the Board of Directors may in good faith deem necessary or advisable. The Company will
issue a press release relating to any material amendment made to the Rights Plan prior to the
Meeting and will advise
the shareholders of any such amendment at the Meeting. Material amendments or supplements to the
Rights Plan will require, subject to the regulatory authorities, the prior approval of the
shareholders or, after the Separation Time, holders of Rights.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 9
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

Canadian Income Tax Consequences of the Rights Plan

Under the Income Tax Act (Canada) (the “Tax Act”), while the matter may be debated, the issue of
the Rights under the Rights Plan may be a taxable benefit, the fair market of value of which must
be included in the income of a recipient. The Company considers that the Rights, when issued, will
have no or negligible monetary value, there being only a remote possibility that the Rights will
ever be exercised. The Rights will be considered to have been acquired at no cost. The holder of
Rights may realize income or be subject to withholding tax under the Tax Act if the Rights become
exercisable, are exercised and are otherwise disposed of.

The information provided above is of a general nature and is not intended to constitute, nor should
it be construed as, legal or tax advice to any particular holder of Common Shares. Such holders are
advised to consult their own tax advisors regarding the consequences of acquiring, holding,
exercising or otherwise disposing of their Rights, taking into account their own particular
circumstances and applicable federal, provincial, territorial or foreign legislation.

Recommendation of the Board of Directors

At the Meeting, shareholders will be asked to consider and, if deemed advisable, to approve the
Rights Plan by passing Resolution 2010-1, substantially in the form of the resolution attached as
Appendix A to this Circular. Resolution 2010-1 must be passed by a majority of the votes cast by
shareholders entitled to vote who are represented in person or by proxy at the Meeting and who vote
in respect of that resolution.

The Board of Directors considers the approval of the Rights Plan to be appropriate and in the best
interests of the Company and recommends that shareholders vote in favour of Resolution 2010-1 to
approve the Rights Plan.

Unless instructions are given to vote against, or abstain from voting on, Resolution 2010-1, the
persons whose names appear in the enclosed form of proxy will vote FOR the passing of Resolution
2010-1.

E. Other Matters to be Acted Upon

The Company will consider and transact such other business as may properly come before the
Meeting or any adjournment thereof. Management of the Company knows of no other matters to come
before the Meeting other than those referred to in the Notice of Meeting. Should any other matters
properly come before the Meeting, the Common Shares represented by the proxy solicited hereby will
be voted on such matter in accordance with the best judgment of the persons voting the proxy.

			
	 	 	 
	Information Relating to the Meeting
	 	Page 10
	Management Proxy Circular
	 	Theratechnologies Inc. 

 

 

ITEM II. COMPENSATION

The compensation of the executive officers and directors of the Company is determined by the
compensation committee of the Company (the “Compensation Committee”). The Compensation Committee is
composed of four (4) independent directors, namely A. Jean de Grandpré, who is the chair of the
Compensation Committee, Paul Pommier, Bernard Reculeau and Jean-Denis Talon. The mandate,
obligations and duties of the Compensation Committee are described in Appendix B to this Circular.
The Compensation Committee reviews the compensation of executive officers at a meeting held after
the end of the Company’s financial year. At this meeting, the Compensation Committee reviews the
compensation of executive officers for the past financial year and determines the compensation for
the ensuing year.

1. Executive Compensation

A. Compensation Discussion & Analysis

Objectives of the Compensation Program

To achieve its business plan, the Company requires a strong and capable executive team. This
justifies the need for an executive program that will attract, retain, motivate and reward its
executive officers. The Company is committed to a compensation policy that is competitive and
drives business performance.

What the Compensation Program is Designed to Reward

The compensation program of the Company (the “Compensation Program”) is designed to reward the
executive officers for implementing strategies, both in the short and the long term, to realize the
business plan of the Company to advance its drug development and commercialization programs. It is
also designed to enhance its share value and, thereby, create economic value.

The Compensation Program provides reasonable and competitive total executive compensation.
Remuneration and incentive components are established to compete with remuneration practices of
similar companies that are involved in the biopharmaceutical and pharmaceutical industries.

To establish base salary and bonus compensation levels, the Company generally studies, among other
things, the competitive market environment and reviews information published in the Rx & D
Compensation Survey and the proxy circulars of other publicly listed biotechnology companies whose
stage of development and market capitalization are similar or more advanced than those of the
Company. The Compensation Committee also takes into consideration the financial needs of the
Company, its business plan and the Company’s annual corporate objectives before determining the
Company’s own Compensation Program.

At the beginning of the financial year 2009, the Compensation Committee met to determine the base
salary of each executive officer. In order to set the base salary of its executive officers for
that financial year, the Compensation Committee considered publicly available economic data
regarding the variation of the Consumer Price Index and publicly available data regarding
forecasted salary percentage increase for that year. The Compensation Committee also considered the
importance of the objectives to be attained by the executive officers and the Company during that
year. No independent third-party report was prepared. However, at the end of the financial year
2009, the Compensation Committee retained the services of Towers Perrin, an independent third-party

			
	 	 	 
	Statement of Executive Compensation
	 	Page 11
	Management Proxy Circular
	 	Theratechnologies Inc.

 

consulting firm, to conduct an annual comparative analysis of the compensation paid to its
executive officers against the compensation paid to executive officers in various companies. Towers
Perrin’s analysis was based on a reference market of the following 19 companies (the “Benchmarked
Companies”):

	 	•	 	AEterna Zentaris Inc.

	 	•	 	Angiotech Pharmaceuticals Inc.

	 	•	 	AstraZeneca Canada Inc.

	 	•	 	Bayer Inc.

	 	•	 	Beckman Coulter Canada Inc.

	 	•	 	Biogen Idec Canada Inc.

	 	•	 	BioMS Medical Corp.

	 	•	 	Cardiome Pharma Corp.

	 	•	 	Eli Lilly Canada Inc.

	 	•	 	Hoffman — La Roche Limited

	 	•	 	Labopharm Inc.

	 	•	 	Life Technologies Corporation

	 	•	 	MDS Inc.

	 	•	 	Methylgene Inc.

	 	•	 	Bellus Health Inc.

	 	•	 	Patheon Inc.

	 	•	 	QLT Inc.

	 	•	 	Sanofi Pasteur Limited

	 	•	 	Transition Therapeutics Inc.

The Benchmarked Companies were reviewed and agreed to by the Compensation Committee.

Overall, Towers Perrin’s report concluded that the aggregate compensation paid to the Named
Executive Officers (as defined below) of the Company was below the median and, in certain
circumstances, at the median of the aggregate compensation paid by the Benchmarked Companies to
individuals holding the same position as those of the Named Executive Officers.

Decision-Making Process

The proposed annual compensation for each of the executive officers, other than for the President
and Chief Executive Officer, is presented by the President and Chief Executive Officer to the
Compensation Committee and reviewed by the Compensation Committee. The compensation for the
President and Chief Executive Officer is determined by the Compensation Committee. The Compensation
Committee reports and makes a recommendation to the Board of Directors on the proposed compensation
of executive officers. The Board of Directors approves grants of options if, upon the
recommendation of the Compensation Committee, it deems it advisable.

Elements of Compensation Program

The major elements of the Company’s executive Compensation Program are base salary, short-term
performance reward program that takes the form of cash bonuses, and long-term incentives through
the granting of stock options. All proposed changes to any compensation component of an executive
officer are first reviewed internally by the President and Chief Executive Officer and the Senior
Executive Vice President and Chief Financial Officer. The proposed changes are then presented to
the Compensation Committee.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 12
	Management Proxy Circular
	 	Theratechnologies Inc.

 

Base Salary

Base salaries for each of the executive officers are based on the experience, expertise and
competencies of each executive officer. In reference to the Benchmarked Companies used for
comparison, the salaries of the Named Executive Officers and other executive officers are generally
at the median (50th percentile). However, the Compensation Committee has no firm policy
on setting the base salary at the median and, accordingly, base salaries may be set below or above
the median.

Performance Reward Program

The short-term performance reward program is designed to recognize the contribution of each
executive officer in helping the Company to attain its corporate objectives and to increase its
value. Bonuses are granted if the annual corporate objectives are met by the Company and in
accordance with the individual performance and the results achieved or surpassed by such individual
in connection with such corporate objectives. When and if the Company generates significant
revenues from the sale of his products, financial criteria will also be factored into the
determination of this program.

The target bonus payment for each of the President and Chief Executive Officer and the Senior
Executive Vice President and Chief Financial Officer is set at 50% of their respective base salary.
For the other three Named Executive Officers, the target bonus payment is set at 33 1/3% of their
respective base salary. These target bonus payments are at the 75th percentile when
compared against the Benchmarked Companies, except for the target bonus payment of the President
and Chief Executive Officer which is at the median.

For the year ended November 30, 2009, the Company’s principal objective was to file a complete New
Drug Application to the Food and Drug Administration in the United States and to file it by the end
of the second quarter. The second corporate objective of the Company consisted in organizing
working committees with our commercial partner in the United States for the preparation of the
commercialization of tesamorelin in such country further to the execution of our collaboration and
licensing agreement with EMD Serono, Inc. at the beginning of our fiscal year 2009. The third
corporate objective of the Company was related to the negotiations of supply agreements with
third-party service providers to ensure that the Company would have the manufacturing capacity to
supply tesamorelin to its commercial partner in the United States for commercial sale in this
country. The fourth corporate objective of the Company consisted in exploring the potential of
tesamorelin to be approved in countries other than the United States for the treatment of excess
abdominal fat in HIV-infected patients with lipodystrophy while seeking partners to commercialize
tesamorelin in those countries. The fifth corporate objective of the Company consisted in pursuing
the evaluation of other clinical programs in which tesamorelin could be developed. Finally, the
last objective was to meet each of these objectives in a cost-efficient manner to conserve the
Company’s cash position and to manage its burn rate.

The objectives of the Named Executive Officers were aligned with those of the Company. The
Compensation Committee did not mathematically weight the objectives of the Company against each
other and the objectives of the Named Executive Officers against those of the Company in
determining the compensation of the Named Executive Officers for the last financial year. The
Compensation Committee rather considered all objectives with the attainment of the first corporate
objective as being the most relevant one in order to set the compensation of the Named Executive
Officers for the last financial year.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 13
	Management Proxy Circular
	 	Theratechnologies Inc.

 

Long-Term Incentive Program

The Company’s long-term incentive program is composed of its share option plan (the “Share Option
Plan”) which was originally adopted on December 6, 1993, and subsequently amended from time to
time, in order to attract, retain, motivate employees in key positions and align their interests
with those of the Company’s shareholders by allowing optionees to participate in the increased
value of the Common Shares. The Company has no share-based award. The Company has a share purchase
plan but the share purchase plan is available to all employees of the Company and the decision to
subscribe for Common Shares under this plan rests with each employee. For a description of the
share purchase plan, see “Other Information — Description of the Share Purchase Plan” below.

The number of options granted is determined on the basis of the position of each executive officer,
the attainment of corporate objectives and the value of the options at the time of grant as part of
the total compensation of an executive officer. When assessing whether options should be granted to
an executive officer, the Compensation Committee also factors in the number of options held by an
executive officer, their vesting periods, expiry dates and exercise prices. When compared against
the value of options granted by the Benchmarked Companies to individuals holding the same positions
as those of the Named Executive Officers, the estimated annualized value of the options granted by
the Company during the last five (5) years to its Named Executive Officers is below and, in certain
circumstances, at the median.

Description of the Share Option Plan

A maximum of 5,000,000 Common Shares have been reserved for stock option grants under the Share
Option Plan, of which, as at the date of the Circular, 999,001 options remain available for
issuance.

The Board of Directors administers the Share Option Plan. The Board of Directors designates the
optionees and determines the number of Common Shares underlying these options, the vesting period,
the exercise price and the expiry date of each option, as well as all other related matters, the
whole in compliance with the terms of the Share Option Plan and applicable legislative provisions
established by the securities regulatory authorities. Options granted to executive officers
generally vest as to 33 1/3% on each year starting twelve (12) months after the date of grant. The
Board of Directors can modify or terminate the Share Option Plan subject to compliance with the
rules set forth by regulatory authorities. However, certain amendments require the approval of a
majority of the voting shareholders of the Company.

Unless otherwise determined by the Board of Directors, the options granted pursuant to the Share
Option Plan may be exercised within a maximum period of ten (10) years following their date of
grant, unless the optionee’s employment is terminated, other than for death, in which case the
optionee’s unexercised vested options, if any, may be exercised within a period of one hundred
eighty (180) days following the date of the employee’s termination. In the event of the death of an
optionee prior to the expiry date of his options, the optionee’s legal personal representative may
exercise the optionee’s unexercised vested options within twelve (12) months after the date of the
optionee’s death. The options granted in accordance with the Share Option Plan cannot be
transferred or assigned.

The exercise price at which the options may be granted pursuant to the Share Option Plan cannot be
less than the closing price of the Common Shares on the TSX on the day preceding the date of grant
of the options.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 14
	Management Proxy Circular
	 	Theratechnologies Inc.

 

In addition, the Share Option Plan states that the number of Common Shares that may be issued
to insiders, at any time, under all security based compensation arrangements of the Company, cannot
exceed 10% of the outstanding Common Shares of the Company, and the number of Common Shares issued
to insiders, within any one year period, under all security based compensation arrangements, cannot
exceed 10% of the outstanding Common Shares. The number of Common Shares that may be issued to
non-employee directors, within any one year period, under all security based compensation
arrangements, cannot exceed 0.5% of the outstanding Common Shares of the Company.

During the financial year ended November 30, 2009, the Company granted options under the Share
Option Plan providing for the purchase of 680,500 Common Shares. From December 1, 2009 to February
22, 2010, the Company granted 265,000 options under the Share Option Plan, 155,000 of which were
granted to the Named Executive Officers as part of their compensation for the last financial year
ended November 30, 2009.

The following table sets forth the information regarding the equity compensation plan of the
Company as at November 30, 2009.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Number of Securities	 	 	 	 	 	 	 	 
	 	 	to be Issued upon	 	 	 	 	 	 	 	 
	 	 	Exercise of	 	 	 	 	 	 	Number of Securities	 
	 	 	Outstanding Options	 	 	 	 	 	 	Remaining Available	 
	 	 	(% of Issued and	 	 	Weighted-average	 	 	for Future Issuance	 
	 	 	Outstanding Share	 	 	Exercise Price of	 	 	under Equity	 
	Plan Category	 	Capital)	 	Outstanding Option	 	Compensation Plan	 
	Equity Compensation

Plan Approved by

Shareholders
	 	 	 

2,665,800

 (4.41%)		 	$	 

 

5.20	 	 	 	1,244,834	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Equity Compensation

Plans Not Approved

by Shareholders
	 	 	—	 	 	 	—	 	 	 	—	 
	 
 	 
	Total
	 	 	2,665,800	 	 	$	5.20	 	 	 	1,244,834	 
	 	 

B. Summary Compensation Table

The summary compensation table below details compensation for the financial year ended November 30,
2009 for each of the President and Chief Executive Officer, the Senior Executive Vice President and
Chief Financial Officer, and the three other most highly compensated executive officers of the
Company (collectively the “Named Executive Officers”) for services rendered in all capacities.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 15
	Management Proxy Circular
	 	Theratechnologies Inc.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Non-equity incentive plan compensation ($)	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Option-	 	 	 	 	 	 	 	 	 	All other	 	 	 	 
	Name and	 	 	 	 	 	 	 	 	 	 	 	 	 	based	 	 	Annual	 	 	Long-term	 	 	Pension	 	 	compen-	 	 	 	 
	principal	 	 	 	 	 	Salary	 	 	Share-based awards	 	 	awards(1) (2)	 	 	incentive	 	 	incentive	 	 	value	 	 	sation(13)	 	 	Total compensation	 
	position	 	Year	 	 	($)	 	 	($)	 	 	($)	 	 	plans	 	 	plans	 	 	($)	 	 	($)	 	 	($)	 
	 
	Yves Rosconi

President and 

Chief Executive

Officer
	 	 	2009	 	 	 	426,635	 	 	 	—	 	 	 	80,820	(3)	 	 	225,000	(8)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	732,455	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Luc Tanguay 

Senior Executive 

Vice President and 

Chief Financial 

Officer
	 	 	2009	 	 	 	353,354	 	 	 	—	 	 	 	67,350	 (4)	 	 	176,000	 (9)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	596,704	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Christian Marsolais 

Vice President, 

Clinical Research 

and Medical Affairs
	 	 	2009	 	 	 	220,846	 	 	 	—	 	 	 	156,040	 (5)	 	 	100,000	 (10)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	476,886	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Martine Ortega 

Vice President, 

Compliance and 

Regulatory Affairs
	 	 	2009	 	 	 	215,827	 	 	 	—	 	 	 	125,165	 (6)	 	 	110,000	 (11)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	450,992	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Jocelyn Lafond 

Vice President, 

Legal Affairs, 

and Corporate 

Secretary
	 	 	2009	 	 	 	200,769	 	 	 	—	 	 	 	142,570	 (7)	 	 	66,000	 (12)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	409,339	 

 

			
	(1)	 	The value of the awards is comprised of two grants that occurred during the last financial
year. The first grant was made on December 18, 2008 (the “December 2008 Grant”) and the second
occurred on December 8, 2009 (the “December 2009 Grant”). Only the value of the options
received by Ms. Ortega, Mr. Marsolais and Mr. Lafond as part of the December 2008 Grant and
resulting as compensation for the financial year ended November 30, 2009 has been included in
this table. The value of the option-based awards was calculated using the Black-Scholes-Merton
model using the following assumptions:

	 	(a)	 	December 2008 Grant:

	 
	 	(i)	 	Risk-free interest rate: 1.79%;
	 
	 	(ii)	 	Expected volatility in the market price of the Common Shares: 79.33%;
	 
	 	(iii)	 	Expected dividend yield: 0%; and
	 
	 	(iv)	 	Expected life: 6 years.
	 
	 	 	 	Fair value per option: $1.235.

	 
	 	(b)	 	December 2009 Grant:

	 
	 	(i)	 	Risk-free interest rate: 2.46%;
	 
	 	(ii)	 	Expected volatility in the market price of the Common Shares: 80.96%;
	 
	 	(iii)	 	Expected dividend yield: 0%; and
	 
	 	(iv)	 	Expected life: 6 years.
	 
	 	 	 	Fair value per option: $2.694

 

			
	(2)	 	The options granted as part of the December 2008 Grant vest over a three (3) year period as
to 33 1/3% beginning December 18, 2009. The options granted as part of the December 2009 Grant
vest over a three (3) year period as to 33 1/3% beginning on December 8, 2010.
	 
	(3)	 	Mr. Rosconi was granted 30,000 options as part of the December 2009 Grant.
	 
	(4)	 	Mr. Tanguay was granted 25,000 options as part of the December 2009 Grant.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 16
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

			
	(5)	 	Mr. Marsolais was granted 35,000 options as part of the December 2009 Grant. Mr. Marsolais
was also granted 50,000 options as part of the December 2008 Grant, of which 25,000 were
granted pursuant to the terms of his employment agreement and 25,000 were granted further to
his appointment as Vice President in August 2007. Subject to Mr. Marsolais being employed by
the Company, these 50,000 options were scheduled to be granted in the financial year 2008.
However, as a result of the strategic review process that was ongoing during this financial
year, the Board of Directors decided to defer the grant of those options until completion of
the strategic review process.
	 
	(6)	 	Ms. Ortega was granted 35,000 options as part of the December 2009 Grant. Ms. Ortega was also
granted 25,000 options as part of the December 2008 Grant further to her appointment as Vice
President in August 2007. Subject to Ms. Ortega being employed by the Company, these 25,000
options were scheduled to be granted in the financial year 2008. However, as a result of the
strategic review process that was ongoing during this financial year, the Board of Directors
decided to defer the grant of those options until completion of the strategic review process.
	 
	(7)	 	Mr. Lafond was granted 30,000 options as part of the December 2009 Grant. Mr. Lafond was also
granted 50,000 options as part of the December 2008 Grant, of which 25,000 were granted
pursuant to the terms of his employment agreement and 25,000 were granted further to his
appointment as Vice President in August 2007. Subject to Mr. Lafond being employed by the
Company, these 50,000 options were scheduled to be granted in the financial year 2008.
However, as a result of the strategic review process that was ongoing during this financial
year, the Board of Directors decided to defer the grant of those options until completion of
the strategic review process.
	 
	(8)	 	The amount received by Mr. Rosconi represents 106% of his targeted bonus ($212,873). As
President and Chief Executive Officer of the Company, Mr. Rosconi’s objectives were aligned
with the Company’s objectives. The Compensation Committee determined that he had exceeded his
objectives by leading the scientific and regulatory teams in filing a New Drug Application to
the Food and Drug Administration in the United States before the end of the second quarter.
	 
	(9)	 	The amount received by Mr. Tanguay represents 100% of his targeted bonus ($176,000). As
Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Tanguay’s
objectives were aligned with those of the Company and included (i) managing the Company’s
liquidities to ensure the corporate objectives would be attained in a cost-efficient manner
and according to the annual budget; (ii) supervising the negotiation of supply agreements with
third parties for the manufacture of tesamorelin on a commercial scale; (iii) overseeing the
internal controls and process of the Company for compliance with securities regulation; (iv)
supervising the process regarding the preparation of the Company to the new IFRS accounting
rules; and (v) overseeing the investors’ relations programme.
	 
	(10)	 	The amount received by Mr. Marsolais represents 135% of his targeted bonus ($73,615). As Vice
President, Clinical Research and Medical Affairs, of the Company, Mr. Marsolais’s objective
were aligned with those of the Company and consisted in the preparation and completion of the
New Drug Application to be filed with the Food and Drug Administration of the United States.
	 
	(11)	 	The amount received by Ms. Ortega represents 153% of her targeted bonus ($71,942). As Vice
President, Compliance and Regulatory Affairs, of the Company, Ms. Ortega’s objectives were
aligned with those of the Company and included (i) leading the preparation of the New Drug
Application to ensure compliance with the Federal Food, Drug, and Cosmetic Act (United
States); and (ii) managing the filing process of the New Drug Application with the Food and
Drug Administration in the United States.
	 
	(12)	 	The amount received by Mr. Lafond represents 99% of his targeted bonus ($66,922). As Vice
President, Legal Affairs, and Corporate Secretary, of the Company, Mr. Lafond’s objectives
were aligned with those of the Company. The main objective of Mr. Lafond consists in
overseeing the legal needs of the Company. In addition, the Compensation Committee determined
that he had achieved the following objectives (i) overseeing the anti-trust issues regarding
the execution of the collaboration and licensing agreement with
EMD Serono, Inc.; (ii) assisting with the negotiations of the supply agreements to manufacture
tesamorelin on a commercial scale; and (iii) supporting the legal needs of both the clinical
research and regulatory teams.
	 
	(13)	 	Perquisites for each Named Executive Officer have not been included as they do not reach the
prescribed threshold of the lesser of $50,000 and 10% of each of the respective Named
Executive Officer’s salary for the last financial year.
	 
	 	 	C. Incentive Plan Awards
	 
	 	 	Outstanding Option-Based Awards and Share-Based Awards
	 
	 	 	The table below details the outstanding option-based awards and share-based awards as at November
30, 2009 for each of the Named Executive Officers.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 17
	Management Proxy Circular
	 	Theratechnologies Inc.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Option-Based Awards	Share-Based Awards	 
	 	 	Number of	 	 	 	 	 	 	 	 	 	 		 	 	Number of shares	 	 	Market or payout	 
	 	 	securities	 	 	 	 	 	 	 	 	 	 	Value of unexercised	 	 	or units of shares	 	 	value of	 
	 	 	underlying	 	 	Option exercice	 	 	 	 	 	 	in-the-money	 	 	that have not	 	 	share-based awards	 
	 	 	unexercised options	 	 	price	 	 	Option expiration	 	 	options (1)	 	 	vested	 	 	that have not	 
	Name	 	(#)	 	 	($)	 	 	date	 	 	($)	 	 	(#)	 	 	vested ($)	 
	 
	Yves Rosconi
	 	 	133,334	 	 	 	2.61	 	 	 	2014.10.01	 	 	 	90,667	 	 	 	—	 	 	 	—	 
	President and
	 	 	133,334	 	 	 	1.24	 	 	 	2015.10.01	 	 	 	273,335	 	 	 	 	 	 	 	 	 
	Chief Executive Officer
	 	 	25,000	 	 	 	8.23	 	 	 	2017.01.12	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	25,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	37,250	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Luc Tanguay
	 	 	200,000	 	 	 	10.40	 	 	 	2011.10.30	 	 	 	—	 	 	 	—	 	 	 	—	 
	Senior Executive
	 	 	200,000	 	 	 	8.00	 	 	 	2012.10.30	 	 	 	—	 	 	 	 	 	 	 	 	 
	Vice President and
	 	 	125,000	 	 	 	1.94	 	 	 	2016.02.08	 	 	 	168,750	 	 	 	 	 	 	 	 	 
	Chief Financial Officer
	 	 	25,000	 	 	 	8.23	 	 	 	2017.01.12	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	20,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	29,800	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Christian Marsolais
	 	 	25,000	 	 	 	11.48	 	 	 	2017.07.11	 	 	 	—	 	 	 	—	 	 	 	—	 
	Vice President,
	 	 	25,000	 	 	 	10.60	 	 	 	2017.08.06	 	 	 	—	 	 	 	 	 	 	 	 	 
	Clinical Research
	 	 	1,000	 	 	 	8.50	 	 	 	2018.01.30	 	 	 	—	 	 	 	 	 	 	 	 	 
	and Medical Affairs
	 	 	65,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	96,850	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Martine Ortega
	 	 	25,000	 	 	 	1.42	 	 	 	2016.07.06	 	 	 	46,750	 	 	 	—	 	 	 	—	 
	Vice President,
	 	 	10,000	 	 	 	8.23	 	 	 	2017.01.12	 	 	 	—	 	 	 	 	 	 	 	 	 
	Compliance and
	 	 	25,000	 	 	 	11.48	 	 	 	2017.07.11	 	 	 	—	 	 	 	 	 	 	 	 	 
	Regulatory Affairs
	 	 	25,000	 	 	 	10.60	 	 	 	2017.08.06	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	1,000	 	 	 	8.50	 	 	 	2018.01.30	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	40,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	59,600	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Jocelyn Lafond
	 	 	25,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	—	 	 	 	—	 
	Vice President,
	 	 	25,000	 	 	 	10.60	 	 	 	2017.08.06	 	 	 	—	 	 	 	 	 	 	 	 	 
	Legal Affairs,
	 	 	65,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	96,850	 	 	 	 	 	 	 	 	 
	and Corporate

Secretary
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

			
	(1)	 	The value of unexercised in-the-money options at financial year end is the difference between
the closing price of the Common Shares on November 30, 2009 ($3.29) on the TSX and the
respective exercise prices of the options. The value shown in this table does not represent
the actual value that a Named Executive Officer would have received if the options had been
exercised as at November 30, 2009 since some of these options were not fully vested as of that
date and, therefore, were not exercisable.

Incentive Plan Awards — Value vested or earned during the year

The table below shows the value vested or earned during the year under each incentive plan as at
November 30, 2009 for each of the Named Executive Officers.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 18
	Management Proxy Circular
	 	Theratechnologies Inc.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Non-equity incentive	 
	 	 	Option-based awards	 	 	Share-based awards	 	 	plan compensation	 
	 	 	Value vested during	 	 	Value vested	 	 	Value earned	 
	 	 	the year(1)	 	 	during the year	 	 	during the year	 
	Name	 	($)	 	 	($)	 	 	($)	 
	Yves Rosconi 

President and

Chief Executive Officer
	 	—	 	 	—	 	 	225,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Luc Tanguay 

Senior Executive 

Vice President and 

Chief Financial Officer
	 	—	 	 	—	 	 	176,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Christian Marsolais 

Vice President, 

Clinical Research 

and Medical Affairs
	 	—	 	 	—	 	 	100,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Martine Ortega 

Vice President, 

Compliance and 

Regulatory Affairs
	 	7,167 (2)	 	 	—	 	 	110,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Jocelyn Lafond 

Vice President, 

Legal Affairs, 

and Corporate Secretary
	 	—	 	 	—	 	 	66,000	 

 

			
	(1)	 	The value is determined by assuming that the options vested during the financial year would
have been exercised on the vesting date. The value corresponds to the difference between the
closing price of the Common Shares on the TSX on the vesting date and the exercise price of
the options on that date.
	 
	(2)	 	8,334 options having an exercise price of $1.42 vested on July 6, 2009. On that date, the
closing price of the Common Shares on the TSX was $2.28.

D. Termination and Change of Control Provisions

Below is a summary of the employment agreements of each of the Named Executive Officers together
with a table detailing the value of the severance payment that would be payable by the Company to
each Named Executive Officer pursuant to his employment agreement if one of the events described in
the table had occurred on November 30, 2009.

Yves Rosconi

President and Chief Executive Officer

On October 21, 2004, the Company entered into an employment agreement for an indeterminate term
with Mr. Yves Rosconi. In addition to his base salary, Mr. Rosconi is entitled to the Company’s
benefits program and is eligible to receive an annual bonus based on attainment of objectives set
annually by the Company’s Board of Directors. Mr. Rosconi was also entitled to stock options, which
have all been granted. These options vested over a three-year period from the date of grant. Under
the terms of the agreement, Mr. Rosconi agreed to non-competition, non-solicitation, non-disclosure
and assignment of intellectual property provisions in favour of the Company. If the Company
terminates Mr. Rosconi’s employment without just and sufficient cause, he will receive an

			
	 	 	 
	Statement of Executive Compensation
	 	Page 19
	Management Proxy Circular
	 	Theratechnologies Inc.

 

amount equal to twelve (12) months of compensation (including bonus — based on the last
granted — and the value of the Company’s benefits to which he was then entitled). The payment of
this amount will be the sole monetary obligation of the Company. Furthermore, in the event of a
“Change of Control” (as defined below), his employment agreement provides for an indemnity equal to
twenty-four (24) months of compensation (including bonus — based on the last granted — and the
value of the Company’s benefits to which he was then entitled) if Mr. Rosconi’s employment is
terminated by the Company, and twelve (12) months if Mr. Rosconi resigns on his own free will. In
Mr. Rosconi’s agreement, a “Change of Control” is defined as a successful take-over bid, as such
term is defined in the Securities Act (Québec).

	 	 	 	 	 	 	 	 	 
	 	 	Severance	 	 	Value of Stock Options(1)	 
	Events	 	($)	 	 	($)	 
	Retirement (2)
	 	 	—	 	 	 	364,002	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
without Just Cause (2)
	 	 	678,535	 (4)	 	 	364,002	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
in the event of
a Change of Control (3)
	 	 	1,357,070	 (4)	 	 	401,252	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation
in the event of
a Change of Control (3)
	 	 	678,535	 (4)	 	 	401,252	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation (2)
	 	 	—	 	 	 	364,002	 

 

			
	(1)	 	The value assumes that upon the occurrence of an event, all vested options would be
exercised. The value is the difference between the closing price of the Common Shares on
November 30, 2009 on the TSX ($3.29) and the respective exercise price of each vested option
as at November 30, 2009.
	 
	(2)	 	Under the Share Option plan, the termination of a person’s employment with the Company
entitles him to exercise his vested options over a six-month period after the termination
date.
	 
	(3)	 	Given the different definitions of “Change of Control” used in the employment agreements of
the Named Executive Officers, in computing the value of the stock options in the event of a
Change of Control, the Company assumed that all unvested options would vest as per the terms
of Section 5.5 of its Share Option Plan and that all vested options having an exercise price
lower than the closing price of the Common Shares on November 30, 2009 on the TSX ($3.29)
would be exercised.
	 
	(4)	 	As at November 30, 2009, the last bonus paid to Mr. Rosconi was the bonus he received for the
financial year 2008 which amounted to $230,000.

Luc Tanguay

Senior Executive Vice President and Chief Financial Officer

The Company entered into an employment agreement for an indeterminate term with Mr. Luc Tanguay on
October 30, 2001. His agreement was subsequently amended on May 9, 2002, June 7, 2004 and February
8, 2006. In addition to his base salary, Mr. Tanguay is entitled to the Company’s benefits program
and is eligible to receive an annual bonus based on the attainment of annual objectives. Mr.
Tanguay was also entitled to stock options, which have all been granted. Under the terms of the
agreement, Mr. Tanguay agreed to non-competition, non-solicitation, non-disclosure and assignment
of intellectual property provisions in favour of the Company. If the Company terminates the
employment of Mr. Tanguay without just and sufficient cause, he will receive an amount equal to
twenty-four (24) months of compensation (including bonus — based on the last granted — and the
value of the Company’s benefits to which he was then entitled). The payment of this amount will be
the sole monetary obligation of the Company. In addition, in the event the employment of Mr.
Tanguay is terminated for any reason, including death, he will be entitled to exercise his stock
options over a 24-month period, subject to the prior expiry of his stock

			
	 	 	 
	Statement of Executive Compensation
	 	Page 20
	Management Proxy Circular
	 	Theratechnologies Inc.

 

options in accordance with their terms. Furthermore, in the event of a “Change of Control” (as
defined below), his employment agreement provides for an indemnity equal to twenty-four (24) months
of compensation (including bonus — based on the last granted — and the value of the Company’s
benefits to which he was then entitled) if Mr. Tanguay’s employment is terminated by the Company,
and twelve (12) months if Mr. Tanguay resigns on his own free will. In Mr. Tanguay’s agreement, a
“Change of Control” is defined as a successful take-over bid, as such term is defined in the
Securities Act (Québec).

	 	 	 	 	 	 	 	 	 
	 	 	Severance	 	 	Value of
 Stock
 Options(1)	 
	Events	 	($)	 	 	($)	 
	Retirement (2)
	 	 	—	 	 	 	168,750	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment without
Just Cause (2)
	 	 	1,140,508	 (4)	 	 	168,750	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
in the event of
a Change of Control (3)
	 	 	1,140,508	 (4)	 	 	198,550	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation
in the event of
a Change of Control (3)
	 	 	570,254	 (4)	 	 	198,550	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation (2)
	 	 	—	 	 	 	168,750	 

 

			
	(1)	 	The value assumes that upon the occurrence of an event, all vested options would be
exercised. The value is the difference between the closing price of the Common Shares on
November 30, 2009 on the TSX ($3.29) and the respective exercise price of each vested option
as at November 30, 2009.
	 
	(2)	 	Under the Share Option plan, the termination of a person’s employment with the Company
entitles him to exercise his vested options over a six-month period after the termination
date.
	 
	(3)	 	Given the different definitions of “Change of Control” used in the employment agreements of
the Named Executive Officers, in computing the value of the stock options in the event of a
Change of Control, the Company assumed that all unvested options would vest as per the terms
of Section 5.5 of its Share Option Plan and that all vested options having an exercise price
lower than the closing price of the Common Shares on November 30, 2009 on the TSX ($3.29)
would be exercised.
	 
	(4)	 	As at November 30, 2009, the last bonus paid to Mr. Tanguay was the bonus he received for the
financial year 2008 which amounted to $195,000.

Christian Marsolais

Vice President, Clinical Research and Medical Affairs

The Company entered into an employment agreement for an indeterminate term with Mr. Christian
Marsolais on April 13, 2007. In addition to his base salary, Mr. Marsolais is entitled to the
Company’s benefits program and is eligible to receive an annual bonus based on attainment of
objectives set annually by the President and Chief Executive Officer. Mr. Marsolais was also
entitled to stock options, which have all been granted. These stock options vest over a three-year
period from
the date of grant. Under the terms of the agreement, Mr. Marsolais agreed to non-competition,
non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of
the Company. If the Company terminates Mr. Marsolais’ employment without just and sufficient cause,
he will receive an amount equal to nine (9) months of his annual base salary. The payment of this
amount will be the sole monetary obligation of the Company.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 21
	Management Proxy Circular
	 	Theratechnologies Inc.

 

	 	 	 	 	 	 	 	 	 
	 	 	Severance	 	 	Value of Stock Options(1)	 
	Events	 	($)	 	 	($)	 
	Retirement (2)
	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
without Just Cause (2)
	 	 	165,634	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
in the event of
a Change of Control (3)
	 	 	165,634	 	 	 	96,850	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation
in the event of
a Change of Control (3)
	 	 	—	 	 	 	96,850	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation (2)
	 	 	—	 	 	 	—	 

 

			
	(1)	 	The value assumes that upon the occurrence of an event, all vested options would be
exercised. The value is the difference between the closing price of the Common Shares on
November 30, 2009 on the TSX ($3.29) and the respective exercise price of each vested option
as at November 30, 2009.
	 
	(2)	 	Under the Share Option plan, the termination of a person’s employment with the Company
entitles him to exercise his vested options over a six-month period after the termination
date.
	 
	(3)	 	Given the different definitions of “Change of Control” used in the employment agreements of
the Named Executive Officers, in computing the value of the stock options in the event of a
Change of Control, the Company assumed that all unvested options would vest as per the terms
of Section 5.5 of its Share Option Plan and that all vested options having an exercise price
lower than the closing price of the Common Shares on November 30, 2009 on the TSX ($3.29)
would be exercised.

Martine Ortega

Vice President, Compliance and Regulatory Affairs

The Company entered into an employment agreement for an indeterminate term with Ms. Martine Ortega
on May 11, 2006. In addition to her base salary, Ms. Ortega is entitled to the Company’s benefits
program and is eligible to receive an annual bonus based on attainment of objectives set annually
by the President and Chief Executive Officer. Ms. Ortega was also entitled to stock options, which
have all been granted. These stock options vest over a three-year period from the date of grant.
Under the terms of the agreement, Ms. Ortega agreed to non-solicitation, non-disclosure and
assignment of intellectual property provisions in favour of the Company. If the Company terminates
Ms. Ortega’s employment without just and sufficient cause, she will receive an amount equal to nine
(9) months of her annual base salary, if her termination occurs: (i) in the context of an internal
reorganization of the Company or (ii) within two (2) years from the date there occurs a “Change of
Control” (as defined below) of the Company. The payment of this amount will be the sole monetary
obligation of the Company. In Ms. Ortega’s agreement, a “Change of Control” is defined as a
transaction resulting in the liquidation or winding-up of the Company, delisting of the Company’s
Common Shares on a stock exchange, the acquisition by a third party of the control of the Company,
the sale of all or substantially all of the assets of the Company or the privatization or a merger
of the Company.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 22
	Management Proxy Circular
	 	Theratechnologies Inc.

 

	 	 	 	 	 	 	 	 	 
	 	 	Severance	 	 	Value of Stock Options(1)	 
	Events	 	($)	 	 	($)	 
	Retirement (2)
	 	 	—	 	 	 	46,750	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment without
Just Cause (2)
	 	 	161,870	 	 	 	46,750	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
in the event of
a Change of Control (3)
	 	 	161,870	 	 	 	106,350	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation
in the event of
a Change of Control (3)
	 	 	—	 	 	 	106,350	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation (2)
	 	 	—	 	 	 	46,750	 

 

			
	(1)	 	The value assumes that upon the occurrence of an event, all vested options would be
exercised. The value is the difference between the closing price of the Common Shares on
November 30, 2009 on the TSX ($3.29) and the respective exercise price of each vested option
as at November 30, 2009.
	 
	(2)	 	Under the Share Option plan, the termination of a person’s employment with the Company
entitles him to exercise his vested options over a six-month period after the termination
date.
	 
	(3)	 	Given the different definitions of “Change of Control” used in the employment agreements of
the Named Executive Officers, in computing the value of the stock options in the event of a
Change of Control, the Company assumed that all unvested options would vest as per the terms
of Section 5.5 of its Share Option Plan and that all vested options having an exercise price
lower than the closing price of the Common Shares on November 30, 2009 on the TSX ($3.29)
would be exercised.

Jocelyn Lafond

Vice President, Legal Affairs, and Corporate Secretary

The Company entered into an employment agreement for an indeterminate term with Mr. Jocelyn Lafond
on March 27, 2007. In addition to his base salary, Mr. Lafond is entitled to the Company’s benefits
program and is eligible to receive an annual bonus based on attainment of objectives set annually
by the Senior Executive Vice President and Chief Financial Officer. Mr. Lafond was also entitled to
stock options, which have all been granted. These stock options vest over a three-year period from
the date of grant. Under the terms of the agreement, Mr. Lafond agreed to non-disclosure and
assignment of intellectual property provisions in favour of the Company. If the Company terminates
Mr. Lafond’s employment without just and sufficient cause, he will receive an amount equal to 12
months of his annual base salary. The payment of this amount will be the sole monetary obligation
of the Company. Furthermore, in the event of a “Change of Control”, his employment agreement
provides for an indemnity equal to 12 months of his annual base salary if his employment is
terminated or if he resigns of his own free will within 24 months from such “Change of Control”. In
Mr. Lafond’s agreement, a “Change of Control” is defined as a take-over bid, as such term is
defined in the Securities Act (Québec), and as any transaction pursuant to which a person acquires
the control of the Company.

			
	 	 	 
	Statement of Executive Compensation
	 	Page 23
	Management Proxy Circular
	 	Theratechnologies Inc.

 

	 	 	 	 	 	 	 	 	 
	 	 	Severance	 	 	Value of Stock Options(1)	 
	Events	 	($)	 	 	($)	 
	Retirement (2)
	 	 	—	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
without Just Cause (2)
	 	 	200,769	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 
	Termination of Employment
in the event of
a Change of Control (3)
	 	 	200,769	 	 	 	96,850	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation
in the event of
a Change of Control (3)
	 	 	200,769	 	 	 	96,850	 
	 
	 	 	 	 	 	 	 	 
	Voluntary Resignation (2)
	 	 	—	 	 	 	—	 

 

			
	(1)	 	The value assumes that upon the occurrence of an event, all vested options would be
exercised. The value is the difference between the closing price of the Common Shares on
November 30, 2009 on the TSX ($3.29) and the respective exercise price of each vested option
as at November 30, 2009.
	 
	(2)	 	Under the Share Option plan, the termination of a person’s employment with the Company
entitles him to exercise his vested options over a six-month period after the termination
date.
	 
	(3)	 	Given the different definitions of “Change of Control” used in the employment agreements of
the Named Executive Officers, in computing the value of the stock options in the event of a
Change of Control, the Company assumed that all unvested options would vest as per the terms
of Section 5.5 of its Share Option Plan and that all vested options having an exercise price
lower than the closing price of the Common Shares on November 30, 2009 on the TSX ($3.29)
would be exercised.

E. Performance Graph

The following graph compares a cumulative annual total shareholder return on a $100 investment in
the Common Shares of the Company (“TH”) with a cumulative total shareholder return on the composite
index S&P/TSX (previously known as the Toronto Stock Exchange 300 (TSE 300 Index)) assuming that
all dividends are reinvested (“S&P”) and the AMEX biotech index (“AMEX Biotech”).

Return on a $100 Investment

from November 30, 2004 to November 30, 2009

			
	 	 	 
	Statement of Executive Compensation
	 	Page 24
	Management Proxy Circular
	 	Theratechnologies Inc.

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	2004	 	 	2005	 	 	2006	 	 	2007	 	 	2008	 	 	2009	 
	 
	Theratechnologies
	 	 	100,00	 	 	 	53,44	 	 	 	133,33	 	 	 	537,04	 	 	 	85,19	 	 	 	174,07	 
	S&P / TSX Composite Index
	 	 	100,00	 	 	 	119,87	 	 	 	141,22	 	 	 	151,60	 	 	 	102,66	 	 	 	126,77	 
	AMEX Biotechnology Index
	 	 	100,00	 	 	 	129,84	 	 	 	148,42	 	 	 	159,78	 	 	 	114,91	 	 	 	171,25	 
	 

The trend shown in the above performance graph indicates that, as at November 30 of each of
the 2005, 2006, 2007, 2008 and 2009 year, the annual total shareholder return on a $100 investment
in the Common Shares of the Company was above the S&P and approximately the same as the AMEX
Biotech. The base salaries of the Named Executives Officers were not linked to the trend regarding
the annual total shareholder return over the last five years. For the same period, shareholder
return was one of the parameters taken into consideration in establishing the value of the
short-term performance reward for the Named Executive Officers.

F. Other Information

Description of the Share Purchase Plan

On February 16, 1999, the Board of Directors adopted a common share purchase plan (the “Share
Purchase Plan”). The Share Purchase Plan was thereafter amended from time to time and, more
recently, by the Board of Directors on February 24, 2009. The last amendments to the Share Purchase
Plan were approved by the shareholders on March 26, 2009 at the Company’s last annual and special
meeting of shareholders.

The Share Purchase Plan entitles full-time and part-time employees of the Company who, on a
Participation Date (as defined below), are residents of Canada, are not under a probationary period
and do not hold, directly or indirectly, five percent (5%) or more of the Company’s outstanding
Common Shares, to directly subscribe for Common Shares of the Company. The Share Purchase Plan
provides that a maximum of 550,000 Common Shares (0.91% of the issued and outstanding Common Shares
as at January 31, 2010) may be offered to employees. During the fiscal year ended November 30,
2009, the Company issued 34,466 Common Shares under the Share Purchase Plan (0.06% of the issued
and outstanding Common Shares as at January 31, 2010). As at the date of the Circular, 210,186
Common Shares remain available for issuance.

On May 1st and November 1st of each year (the “Participation Dates”), an
employee may subscribe for a number of Common Shares under the Share Purchase Plan for an amount
that does not exceed during such year 10% of his annual gross salary during said year. Under the
Share Purchase Plan, the Board of Directors has the authority to suspend, differ or determine that
no subscription of Common Shares will be allowed on a Participation Date if it is in the best
interest of the Company.

The Share Purchase Plan provides that the number of Common Shares that may be issued to insiders,
at any time, under all security based compensation arrangements of the Company, cannot exceed 10%
of the outstanding Common Shares, and the number of Common Shares issued to insiders, within any
one-year period, under all security based compensation arrangements, cannot exceed 10% of the
outstanding Common Shares.

The subscription price for each new Common Share subscribed pursuant to the Share Purchase Plan is
equal to the weighted average closing price of the Common Shares on the Toronto Stock Exchange
during a period of five (5) days prior to a Participation Date. Employees cannot assign or
otherwise alienate their rights in the Share Purchase Plan.

      

			
	Statement of Executive Compensation
	 	Page 25
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

At the election of an employee, the subscription price for Common Shares may be paid in cash
or through an interest-free loan provided by the Company. The loans provided by the Company under
the Share Purchase Plan may be repayable by equal withholdings from a participant’s salary for a
period not exceeding two (2) years. All loans may be prepaid at all times. The loans granted to any
employee at any time must not exceed 10% of his current annual gross salary. All Common Shares
subscribed for through an interest-free loan are hypothecated to secure the full and final
repayment of the loan and are held by the trustee, Computershare, until such full repayment. Loans
are immediately due and repayable upon the occurrence of one of the following events: (i) the
termination of the employment of an employee; (ii) the sale or seizure of the Common Shares being
subject to a hypothec; (iii) the bankruptcy or insolvency of an employee; or (iv) the suspension
of the payment of an employee’s salary or the revocation of his right to salary withholdings.

Shareholder approval is not required for all amendments to the Share Purchase Plan. For example,
the Board of Directors may, without shareholder approval, make certain amendments of the following
nature to the Share Purchase Plan such as: (i) formal minor or technical amendments to any
provision of the Share Purchase Plan; (ii) corrections to any provision of the Share Purchase Plan
containing an ambiguity, defect, error or omission; or (iii) changes that do not require
shareholder approval as hereafter described. However, the following amendments require the approval
by a majority of the shareholders present at a duly called shareholders’ meeting:

	 	(a)	 	any extension of the term of the Share Purchase Plan;
	 
	 	(b)	 	any increase in the number of Common Shares reserved for issuance under the Share
Purchase Plan;
	 
	 	(c)	 	any increase in the number of Common Shares that may be purchased annually by an
employee;
	 
	 	(d)	 	any change in the formula to determine the subscription price of Common Shares; and
	 
	 	(e)	 	any increase in the amount an employee is authorized to borrow from the Company to
purchase Common Shares under the Share Purchase Plan.

Indebtedness of Executive Officers

As at the date of the Circular, none of the executive officers was indebted to the Company, other
than for “Routine Indebtedness” (as defined in Regulation 51-102 respecting Continuous Disclosure
Obligations (Québec)). During the financial year ended on November 30, 2009, none of the executive
officers of the Company was indebted to the Company, other than for “Routine Indebtedness”.

2. Director Compensation

A. Determination of Director Compensation

The Company has adopted a compensation policy for its directors who are not employed on a full-time
basis by the Company under which they are paid an annual retainer fee as well as attendance fees.
In addition, the Company reimburses the reasonable expenses incurred by each director to attend
meetings of the board or meetings of committees. In January 2008, the Compensation Committee met
and reassessed the compensation paid to all board members, committee members and to the chairs of
each committee. The last assessment of the compensation paid to individuals acting as board
members, committee members and chairs of such committees had
occurred in 2004. The assessment was based on a review of public documents filed by Canadian
companies listed on the TSX or NASDAQ market. Criteriae such as fields of operation, market

      

			
	Statement of Executive Compensation
	 	Page 26
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

capitalization, number of employees, stage of development, where applicable, and level of
revenue were taken into consideration by the Compensation Committee in reviewing in 2008 the
compensation paid to board members, committee members and to chairs of each committee. Based on the
recommendation of the Compensation Committee, effective January 1, 2008, the Board of Directors
approved the compensation described in the table below for individuals who are not employees of the
Company who act as board members, committee members and chairs of those committees.

	 	 	 	 	 
	Position at	 	 	 
	Board Level or	 	 	 
	Committee Level	 	Compensation	 
	Annual Retainer to Chair of the Board
	 	$	100,000	 
	Annual Retainer to Board Members
	 	$	20,000	 
	Annual Grant of Options (1)
	 	 	10,000	   (2)
	Attendance Fees Paid for Each Meeting of the Board of Directors

	 	 	 	 
	
- in person
	 	$	2,000	 
	- by conference call
	 	$	1,200	 
	Annual Retainer to Chair of the Audit Committee
	 	$	10,000	 
	Annual Retainer to Chair of each Committee (other than the Audit Committee)
	 	$	6,000	 
	Annual Retainer to Committee Members
	 	$	4,000	 
	Attendance Fees Paid for Each Meeting of a Committee(3)

	 	 	 	 
	
- in person
	 	$	1,500	 
	- by conference call
	 	$	1,200	 

 

			
	(1)	 	Options are usually granted at the board meeting following the annual meeting of
shareholders.
	 
	(2)	 	At the time of the 2008 review, the Compensation Committee had set the annual grant of
options to each director at 10,000. However, as a result of the strategic review process that
was ongoing, the Board of Directors decided that the number of options that each director was
entitled to receive annually was to remain at 5,000. Further to the completion of the
strategic review process, during the last financial year, the Board of Directors passed a
resolution in order to change that number from 5,000 to 10,000.
	 
	(3)	 	No attendance fee is paid for meetings of the Finance Committee.

B. Director Compensation Table

The following table details all components of the compensation provided to the directors of the
Company in the last financial year and the value thereof.

      

			
	Statement of Executive Compensation
	 	Page 27
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Fees earned	 	 	Share-based awards	 	 	Option-based awards(2)	 	 	Non-equity incentive 

plan compensation	 	 	Pension value	 	 	All other compensation	 	 	Total	 
	Name	 	($)	 	 	($)	 	 	($)	 	 	($)	 	 	($)	 	 	($)	 	 	($)	 
	 
	Gilles Cloutier
	 	 	46,767	 	 	 	—	 	 	 	12,740	 	 	 	—	 	 	 	—	 	 	 	1,500	 (3)	 	 	61,007	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	A. Jean de Grandpré
	 	 	62,300	 	 	 	—	 	 	 	12,740	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	75,040	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Robert Goyer (1)
	 	 	38,267	 	 	 	—	 	 	 	12,740	 	 	 	—	 	 	 	—	 	 	 	1,500	 (3)	 	 	52,507	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gérald A. Lacoste
	 	 	58,200	 	 	 	—	 	 	 	12,740	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	70,940	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Paul Pommier
	 	 	179,200	 	 	 	—	 	 	 	12,740	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	191,940	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Bernard Reculeau
	 	 	39,400	 	 	 	—	 	 	 	12,740	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	52,140	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Jean-Denis Talon
	 	 	50,300	 	 	 	—	 	 	 	12,740	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	63,040	 

 

	(1)	 	The services of Mr. Goyer are provided to the Company by Clinipharm (1987) Inc.
(“Clinipharm”), a company controlled by Mr. Goyer, and all cash compensation for the services
of Mr. Goyer is paid to this entity. Based on information received from Clinipharm, Mr. Goyer
received from Clinipharm the amount of $10,000 from December 1, 2008 to June 30, 2009. The
fiscal year-end of Clinipharm is different from that of the Company and the amount to be
received, if any, by Mr. Goyer for the period running from July 1, 2009 to November 30, 2009
is unknown. All options are granted to Mr. Goyer, personally.
	 
	(2)	 	The value of the awards is comprised of one grant that occurred on March 28, 2009 (the
“March 2009 Grant”). As part of the March 2009 Grant, each director was granted 10,000 options
at an exercise price of $1.84. Each option has a ten-year term and vests on the date of grant.
The terms and conditions of those options are governed by the Share Option Plan.

	 	 	The value of the option-based awards was calculated using the Black-Scholes-Merton model using the
following assumptions:
	 
	 	 	(i) Risk-free interest rate: 1.9%;
	 
	 	 	(ii) Expected volatility in the market price of the Common Shares: 80.27%;
	 
	 	 	(iii) Expected dividend yield: 0%; and
	 
	 	 	(iv) Expected life: 6 years.
	 
	 	 	Fair value per option: $1.274
	 
	 	 	The value of the awards does not include the 5,000 options that were granted as part of the
December 2008 Grant since these options were granted as compensation for the financial year 2008.
These 5,000 options were not granted in the financial year 2008 as a result of the strategic review
process that was ongoing during that financial year. These 5,000 options were granted at an
exercise price of $1.80, vested on the date of grant and have a ten-year term. The terms and
conditions of those options are governed by the Share Option Plan.

	(3)	 	This amount was paid to each of Mr. Cloutier and Mr. Goyer, through Clinipharm in the
latter case, for their ad hoc advice on certain clinical matters. Both Mr. Cloutier and Mr.
Goyer were formerly on the scientific committee and used to receive an annual compensation of
$2,000 each to act as such. However, for the financial year ended on November 30, 2009, the
Board of Directors determined that it was in the best interests of the Company to abandon this
committee and to compensate Mr. Cloutier and Mr. Goyer if, and when, their services are
required with attendance fees similar to those paid to members of committees.

C. Incentive Plan Awards

Outstanding Option-Based Awards and Share-Based Awards

The table below details the outstanding option-based awards and the share-based awards as at
November 30, 2009 for each of the directors.

      

			
	Statement of Executive Compensation
	 	Page 28
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Option-Based Awards	Share-Based Awards	 
	 	 	Number of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	securities	 	 	 	 	 	 	 	 	 	 	Value of	 	 	Number of shares	 	 	Market or payout	 
	 	 	underlying	 	 	Option	 	 	 	 	 	 	unexercised	 	 	or units of shares	 	 	value of share-	 
	 	 	unexercised	 	 	exercice	 	 	Option	 	 	in-the-money	 	 	that have not	 	 	based awards that	 
	 	 	options	 	 	price	 	 	expiration	 	 	options(1)	 	 	vested	 	 	have not vested	 
	Name	 	(#)	 	 	($)	 	 	date	 	 	($)	 	 	(#)	 	 	($)	 
	 
	Gilles Cloutier
	 	 	5,000	 	 	 	5.40	 	 	 	2013.05.07	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	5,000	 	 	 	3.68	 	 	 	2014.05.03	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.75	 	 	 	2015.05.06	 	 	 	7,700	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.86	 	 	 	2016.03.30	 	 	 	7,150	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	7,450	 	 	 	 	 	 	 	 	 
	 
	 	 	10,000	 	 	 	1.84	 	 	 	2019.03.28	 	 	 	14,500	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	A. Jean de Grandpré
	 	 	5,000	 	 	 	8.65	 	 	 	2010.05.04	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	5,000	 	 	 	11.80	 	 	 	2011.05.10	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	10.55	 	 	 	2012.05.09	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	5.40	 	 	 	2013.05.07	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	3.68	 	 	 	2014.05.03	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.75	 	 	 	2015.05.06	 	 	 	7,700	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.86	 	 	 	2016.03.30	 	 	 	7,150	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	7,450	 	 	 	 	 	 	 	 	 
	 
	 	 	10,000	 	 	 	1.84	 	 	 	2019.03.28	 	 	 	14,500	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Robert Goyer
	 	 	5,000	 	 	 	1.75	 	 	 	2015.05.06	 	 	 	7,700	 	 	 	—	 	 	 	—	 
	 
	 	 	5,000	 	 	 	1.86	 	 	 	2016.03.30	 	 	 	7,150	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	7,450	 	 	 	 	 	 	 	 	 
	 
	 	 	10,000	 	 	 	1.84	 	 	 	2019.03.28	 	 	 	14,500	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gérald A. Lacoste
	 	 	5,000	 	 	 	1.86	 	 	 	2016.03.30	 	 	 	7,150	 	 	 	—	 	 	 	—	 
	 
	 	 	5,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	7,450	 	 	 	 	 	 	 	 	 
	 
	 	 	10,000	 	 	 	1.84	 	 	 	2019.03.28	 	 	 	14,500	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Paul Pommier
	 	 	5,000	 	 	 	8.65	 	 	 	2010.05.04	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	5,000	 	 	 	11.80	 	 	 	2011.05.10	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	10.55	 	 	 	2012.05.09	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	5.40	 	 	 	2013.05.07	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	3.68	 	 	 	2014.05.03	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.75	 	 	 	2015.05.06	 	 	 	7,700	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.86	 	 	 	2016.03.30	 	 	 	7,150	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	7,450	 	 	 	 	 	 	 	 	 
	 
	 	 	10,000	 	 	 	1.84	 	 	 	2019.03.28	 	 	 	14,500	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Bernard Reculeau
	 	 	5,000	 	 	 	1.86	 	 	 	2016.03.30	 	 	 	7,150	 	 	 	—	 	 	 	—	 
	 
	 	 	5,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	 	 	 	 	 	 

      

			
	Statement of Executive Compensation
	 	Page 29
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Option-Based Awards	Share-Based Awards	 
	 	 	Number of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	securities	 	 	 	 	 	 	 	 	 	 	Value of	 	 	Number of shares	 	 	Market or payout	 
	 	 	underlying	 	 	Option	 	 	 	 	 	 	unexercised	 	 	or units of shares	 	 	value of share-	 
	 	 	unexercised	 	 	exercice	 	 	Option	 	 	in-the-money	 	 	that have not	 	 	based awards that	 
	 	 	options	 	 	price	 	 	expiration	 	 	options(1)	 	 	vested	 	 	have not vested	 
	Name	 	(#)	 	 	($)	 	 	date	 	 	($)	 	 	(#)	 	 	($)	 
	 
	 
	 	 	5,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	7,450	 	 	 	 	 	 	 	 	 
	 
	 	 	10,000	 	 	 	1.84	 	 	 	2019.03.28	 	 	 	14,500	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Jean-Denis Talon
	 	 	5,000	 	 	 	11.80	 	 	 	2011.05.10	 	 	 	—	 	 	 	—	 	 	 	—	 
	 
	 	 	5,000	 	 	 	10.55	 	 	 	2012.05.09	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	5.40	 	 	 	2013.05.07	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	3.68	 	 	 	2014.05.03	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.75	 	 	 	2015.05.06	 	 	 	7,700	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.86	 	 	 	2016.03.30	 	 	 	7,150	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	8.29	 	 	 	2017.03.29	 	 	 	—	 	 	 	 	 	 	 	 	 
	 
	 	 	5,000	 	 	 	1.80	 	 	 	2018.12.18	 	 	 	7,450	 	 	 	 	 	 	 	 	 
	 
	 	 	10,000	 	 	 	1.84	 	 	 	2019.03.28	 	 	 	14,500	 	 	 	 	 	 	 	 	 

 

			
	(1)	 	The value of unexercised in-the-money options at financial year end is the difference
between the closing price of the Common Shares on November 30, 2009 ($3.29) on the TSX and the
respective exercise prices of the options.

Incentive Plan Awards — Value vested or earned during the year

The table below shows the value vested or earned during the year under each incentive plan as at
November 30, 2009 for each of the directors.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	Non-equity incentive	 
	 	 	Option-based awards	 	 	Share-based awards	 	 	plan compensation	 
	 	 	Value vested during	 	 	Value vested	 	 	Value earned	 
	 	 	the year(1)	 	 	during the year	 	 	during the year	 
	Name	 	($)	 	 	($)	 	 	($)	 
	Gilles Cloutier
	 	—	 	 	—	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	A. Jean de Grandpré
	 	—	 	 	—	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Robert Goyer
	 	—	 	 	—	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Gérald A. Lacoste
	 	—	 	 	—	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Paul Pommier
	 	—	 	 	—	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Bernard Reculeau
	 	—	 	 	—	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Jean-Denis Talon
	 	—	 	 	—	 	 	—	 

 

			
	(1)	 	The value is determined by assuming that the options vested during the financial year
would have been exercised on the vesting date. The value corresponds to the difference between
the closing price of the Common Shares on the TSX on the vesting date and the exercise price
of the options on that date. Options granted to directors as part of the March 2009 Grant
vested on their date of grant which was a day where the TSX was closed for business. No value
was recorded for those options since their exercise price was equal to the closing price of
the Common Shares on the day preceding the date of grant of the options.

      

			
	Statement of Executive Compensation
	 	Page 30
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

D. Other Information

Indebtedness of Directors

As at the date of the Circular, none of the directors of the Company and proposed nominee for
election as a director of the Company is indebted to the Company. During the financial year ended
on November 30, 2009, none of the directors of the Company was indebted to the Company.

Liability Insurance of Directors and Officers

The Company purchases liability insurance for its directors and officers in the performance of
their duties. These insurance policies also cover the directors and officers of the Company’s
subsidiaries. During the fiscal year ended November 30, 2009, the policies provided maximum
coverage of $20,000,000 per claim, subject to a $200,000 deductible per occurrence. Premiums paid
by the Company for the policies amounted to $109,000. The policies and the premiums do not
distinguish between the insurance for the directors’ liability and officers’ liability, the
coverage being the same for both groups.

      

			
	Statement of Executive Compensation
	 	Page 31
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

ITEM III. CORPORATE GOVERNANCE DISCLOSURE

The Board of Directors of the Company considers good corporate governance to be important to the
effective operations of the Company and to ensure that the Company is managed so as to optimize
shareholder value. The Nominating and Corporate Governance Committee is responsible for examining
the Company’s needs in this regard and addressing all issues that may arise from its practices.
This Committee ensures that the Company’s corporate governance practices comply with Regulation
58-101 respecting Disclosure of Corporate Governance Practices (Québec) and oversees their
disclosure according to guidelines described in Policy Statement 58-201 to Corporate Governance
Guidelines (Québec) (hereinafter collectively referred to as the “Regulation”).

1. Board of Directors

A. Independence

A majority of the Company’s directors are independent. Seven of the nine Board members meet the
criteria for independence defined by the Regulation, as none of them have a direct or indirect
material relationship with the Company.

	 	 	 	 	 
	Name	 	Independence	 	Material Relationship
	Gilles Cloutier

	 	Yes
	 	None
	A. Jean de Grandpré

	 	Yes
	 	None
	Robert Goyer

	 	Yes
	 	None
	Gérald A. Lacoste

	 	Yes
	 	None
	Paul Pommier

	 	Yes
	 	None
	Bernard Reculeau

	 	Yes
	 	None
	Jean-Denis Talon

	 	Yes
	 	None
	Luc Tanguay

	 	No
	 	Company Management
	Yves Rosconi

	 	No
	 	Company Management

The Chairman of the Board of the Company is Paul Pommier, an independent director within the
meaning of the Regulation.

B. Meetings of the Board

The table below details the directors’ attendances to the Board of Directors’ meetings held in the
fiscal year ended on November 30, 2009.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Name	 	Number of Meetings	 	Attendance	 	Absence
	Gilles Cloutier

	 	 	7	 	 	 	7	 	 	 	0	 
	A. Jean de Grandpré

	 	 	7	 	 	 	7	 	 	 	0	 
	Robert Goyer

	 	 	7	 	 	 	7	 	 	 	0	 
	Gérald A. Lacoste

	 	 	7	 	 	 	7	 	 	 	0	 
	Paul Pommier

	 	 	7	 	 	 	7	 	 	 	0	 
	Bernard Reculeau

	 	 	7	 	 	 	7	 	 	 	0	 
	Jean-Denis Talon

	 	 	7	 	 	 	7	 	 	 	0	 
	Luc Tanguay

	 	 	7	 	 	 	7	 	 	 	0	 
	Yves Rosconi

	 	 	7	 	 	 	7	 	 	 	0	 

			
	 	 	 
	Corporate Governance Disclosure
	 	Page 32
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

A meeting of independent directors, at which non-independent directors and members of
management are not in attendance, is planned as the last item of each Board meeting. Accordingly,
at the conclusion of each Board meeting, the Chairman determines, along with the other independent
directors, the relevance of meeting without non-independent directors and members of management.
During the fiscal year ended November 30, 2009, independent directors held no meeting without
non-independent directors and members of management.

C. Other Board Memberships

As detailed in the following table, only one of the Company’s directors is a board member of an
other reporting issuer.

	 	 	 
	Name	 	Reporting Issuer
	Luc Tanguay

	 	Ambrilia Biopharma Inc.

2. Mandate of the Board of Directors

The Board of Directors adopted the written mandate attached hereto as Appendix C which defines its
role and duties.

Consistent with its mandate of identifying key business risks facing the Company and implementing
systems to manage those risks, during the last financial year, the Board of Directors undertook to
review the various risks faced by the Company. To that end, the Board of Directors delegated to the
Audit Committee the responsibility of supervising the management team involved in this process. The
process is two-pronged: first, it consists in identifying the most important risks and, second, it
consists in reviewing and testing the measures in place to manage the identified risks or,
alternatively, create measures if none is in place. During the last financial year, the first part
of the review process was completed and, in the current financial year, the measures in place will
be tested and, if need be, improved or created.

3. Position Descriptions

The Board of Directors has developed written position descriptions for the Chairman of the Board
and the Chairs of the Board’s Committees. A position description was also developed for the
President and Chief Executive Officer.

4. Orientation and Continuing Education

The Orientation and Continuing Education Policy for newly appointed directors is attached hereto as
Appendix D.

In the last financial year, the members of the Audit Committee attended a seminar organized by the
Company’s auditors, KPMG LLP, on the upcoming IFRS accounting rules. In addition, throughout the
last financial year, the Company provided its directors with reading material covering topics in
various fields, including biotechnology, corporate governance and executive compensation.

In the current financial year, directors will be invited to attend a seminar on Bill 63, the
Business Corporations Act (Québec), the new act intended to replace the Companies Act (Québec).

			
	 	 	 
	Corporate Governance Disclosure
	 	Page 33
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

5. Ethical Business Conduct 

The Board of Directors has not adopted a written ethical business code of conduct for the Company’s
directors, executive officers and employees. However, it has a series of internal policies
substantially covering the same issues as those found in a business code of conduct
(confidentiality, harassment and whistleblowing). In addition, it encourages and promotes ethical
business conduct that upholds integrity and fault prevention.

In the event a director or an executive officer has a material interest in any transaction or
agreement, the matter may initially be reviewed by the Nominating and Corporate Governance
Committee to determine the scope of the interest and its impact on management’s decision-making.
The Committee will report its findings to the Board of Directors, which will take appropriate
action to ensure independent exercise of judgement. In the event a director has a material
interest in any transaction or agreement, such director must disclose, without delay, this conflict
of interest and follow the rules provided by the General By-Laws of the Company.

6. Nomination of Directors 

The Nominating and Corporate Governance Committee is responsible for proposing new candidates for
Board nominations. This Committee is exclusively composed of independent directors. A copy of the
Committee’s Charter is attached hereto as Appendix E.

7. Compensation

A. Independence

The Compensation Committee is responsible for examining matters relating to compensation of
directors and executive officers on behalf of the Board of Directors. The Compensation Committee is
comprised exclusively of independent directors. A detailed description of the procedure used by the
Compensation Committee to establish compensation is provided under Item II of the Circular.

B. Meetings of the Compensation Committee

The table below details members’ attendance to the Compensation Committee’s meetings held in the
financial year ended November 30, 2009.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Name	 	Number of Meetings	 	Attendance	 	Absence
	A. Jean de Grandpré

	 	 	2	 	 	 	2	 	 	 	0	 
	Paul Pommier

	 	 	2	 	 	 	2	 	 	 	0	 
	Bernard Reculeau

	 	 	2	 	 	 	2	 	 	 	0	 
	Jean-Denis Talon

	 	 	2	 	 	 	2	 	 	 	0	 

At each meeting of the Compensation Committee, its members meet without members of management.

8. Audit Committee

A. Independence

The Company has an audit committee comprised of three independent directors, namely Paul Pommier,
who is the Chair, Gérald A. Lacoste and Jean-Denis Talon. Reference is made to section 4.2 of the
Company’s annual information form dated February 23, 2010 for a description of the Audit Committee.

			
	 	 	 
	Corporate Governance Disclosure
	 	Page 34
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

Each member of the Audit Committee has acquired in-depth financial expertise giving each the
ability to read and understand a set of financial statements which presents the breadth and level
of complexity of accounting issues that are generally comparable to those that can reasonably be
expected to be raised in the Company’s financial statements.

B. Meetings of the Audit Committee

The table below details members’ attendance to the Audit Committee’s meetings held in the financial
year ended on November 30, 2009.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Name	 	Number of Meetings	 	Attendance	 	Absence
	Gérald A. Lacoste

	 	 	5	 	 	 	5	 	 	 	0	 
	Paul Pommier

	 	 	5	 	 	 	5	 	 	 	0	 
	Jean-Denis Talon

	 	 	5	 	 	 	5	 	 	 	0	 

A meeting of the members, at which members of management are not in attendance, is planned as
the last item of each Audit Committee meeting when members of management are asked to attend Audit
Committee meetings. Accordingly, at the conclusion of each Audit Committee meeting, the Chairman
determines, along with the members, the relevance of meeting without members of management. During
the last financial year ended November 30, 2009, members held one (1) meeting without members of
management.

9. Other Committees

A. Financing Committee

In addition to the Audit Committee, the Nominating and Corporate Governance Committee and the
Compensation Committee, the Board of Directors created a Financing Committee composed of two
independent directors and two directors who are executive officers of the Company. The Financing
Committee’s mandate is to study and analyze financing matters. No meeting of the Financing
Committee was held in the financial year ended November 30, 2009.

B. Strategic Committee

In August 2007, the Board of Directors created a Strategic Review Committee comprised of four (4)
independent directors, namely Paul Pommier, who is the Chair, Gilles Cloutier, A. Jean de Grandpré
and Gérald A. Lacoste. The mandate of the Strategic Review Committee consisted in reviewing
potential strategic alternatives to enhance shareholder value such as the entering into of a
co-promotion or a partnership agreement with regards to tesamorelin, the finding of a possible
partner, acquiror or target business with a view to complete a merger, a sale or an acquisition. As
a result of the announcement in October 2008 of the collaboration and licensing agreement entered
into between the Company and EMD Serono, Inc., the mandate of the Strategic Review Committee was
changed by the Board of Directors in December 2008 to assist executive officers and recommend to
the Board of Directors a business strategy to further the growth of the Company.

The Strategic Review Committee currently has the following role and responsibilities:

	•	 	to evaluate and review the various business alternatives of the Company for
enhancing shareholder value (the “Strategic Alternatives”);
	 
	•	 	to make recommendations to the Board of Directors with respect to the Strategic
Alternatives and to undertake a process it considers appropriate in order to
provide such recommendations;

			
	 	 	 
	Corporate Governance Disclosure
	 	Page 35
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	•	 	if one of the Strategic Alternatives is approved by the Board of Directors, to
maintain, on behalf of the Board of Directors, a review of its implementation; and

	 
	•	 	to perform any action deemed necessary or advisable to comply with its duties and
obligations under applicable laws.

The table below details the members’ attendance to the Strategic Committee’s meetings held in the
financial year ended on November 30, 2009.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Name	 	Number of Meetings	 	Attendance	 	Absence
	Gilles Cloutier

	 	 	5	 	 	 	4	 	 	 	1	 
	A. Jean de Grandpré

	 	 	5	 	 	 	5	 	 	 	0	 
	Gérald A. Lacoste

	 	 	5	 	 	 	5	 	 	 	0	 
	Paul Pommier

	 	 	5	 	 	 	5	 	 	 	0	 

A meeting of the members, at which members of management are not in attendance, is planned as
the last item of each Strategic Committee meeting when members of management are asked to attend
Strategic Committee meetings. Accordingly, at the conclusion of each Strategic Committee meeting,
the Chairman determines, along with the members, the relevance of meeting without members of
management. During the last financial year ended November 30, 2009, members held two (2) meetings
without members of management.

10. Assessment

While there is no formal process for assessing directors on an ongoing basis, the directors are
free to discuss specific situations from time to time amongst themselves and/or with the Chairman
of the Board and, if deemed necessary, steps are taken to remedy a situation.

			
	 	 	 
	Corporate Governance Disclosure
	 	Page 36
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

ITEM IV. OTHER INFORMATION

1. Additional Documentation

The Company is a reporting issuer in all Canadian provinces and is required to file its financial
statements and Circular with each Canadian Securities Commission. Each year, the Company also files
an Annual Information Form with such commissions. The financial information of the Company is
provided in the Company’s comparative financial statements and Management’s Discussion & Analysis
for its fiscal year ended November 30, 2009. Copies of the Company’s financial statements,
management proxy circular and Annual Information Form may be obtained on request to the Secretary
of the Company at the following address: 2310 Alfred-Nobel Blvd, Montreal, Québec, H4S 2B4 or by
consulting the SEDAR Website at www.sedar.com. The Company may require the payment of a reasonable
fee if the request is made by someone other than a security holder of the Company, unless the
Company is in the course of a distribution of its securities pursuant to a short-form prospectus,
in which case these documents will be provided free of charge.

2. Approval by the Board Of Directors

The content and the sending of this Circular have been approved by the Board of Directors of the
Company on February 22, 2010.

Montreal, Québec, February 23, 2010.

	 	 	 	 	 
	 	Jocelyn Lafond

Corporate Secretary

 	 
	 	 	 
	 	 	 
	 	 	 
	 

			
	 	 	 
	Corporate Governance Disclosure
	 	Page 37
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

APPENDIX A

RESOLUTION OF THE SHAREHOLDERS OF

THERATECHNOLOGIES INC. (THE “COMPANY”)

RESOLUTION 2010-1

SHAREHOLDER RIGHTS PLAN

BE IT RESOLVED:

	1.	 	That the shareholder rights plan adopted by the Board of Directors of the Company on February
10, 2010 be and is hereby approved;
	 
	2.	 	That any director or officer of the Company be and is hereby authorized to execute and
deliver such documents and instruments and to take such other actions as such director or
officer may deem necessary or advisable to give effect to this resolution in his entire
discretion, his determination being conclusively evidenced by the execution and delivery of
such documents or instruments and the taking of such actions.

			
	 	 	 
	Appendix A — Resolution 2010-1
	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

APPENDIX B

COMPENSATION COMMITTEE CHARTER

I. Mandate

The Compensation Committee (the “Committee”) is responsible for assisting the Company’s Board of
Directors (the “Board”) in overseeing the following:

	 	A.	 	compensation of Senior Management;

	 	B.	 	assessment of Senior Management;

	 	C.	 	compensation of Directors;

	 	D.	 	stock option grants;

	 	E.	 	overall increase in total compensation.

II. Obligations and Duties

The Committee carries out the duties usually entrusted to a compensation committee and any other
duty assigned from time to time by the Board. Specifically, the Committee is charged with the
following obligations and duties:

	 	A.	 	Compensation of Senior Management

	 	1.	 	Develop a compensation policy for the Company’s Senior Management,
notably the Senior Management compensation structure, annual salary adjustments
as well as the creation and administration of short and long term incentive
plans, stock options, indirect advantages and benefits proposed by the
President and Chief Executive Officer.

	 	2.	 	Review and establish all forms of compensation to Senior Management.

	 	3.	 	Oversee, as required, employment contracts and terminations of Senior
Management, notably severance pay.

	 	4.	 	Oversee the Company’s annual report on Senior Management compensation
part of the Company’s continuous disclosure requirements under applicable laws
and regulations.

	 	B.	 	Assessment of Senior Management

	 	1.	 	Develop a written position description for the President and Chief
Executive Officer.

	 	2.	 	Establish general objectives annually for the President and Chief
Executive Officer of the Company and for other members of senior management.

			
	 	 	 
	Appendix B — Compensation Committee Charter
	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	 	3.	 	Examine and review annually the President and Chief Executive Officer’s
performance against specific performance criteria pre-established by the
Committee.

	 	4.	 	Examine, in collaboration with the President and Chief Executive
Officer, the annual performance assessment of other senior managers.

	 	C.	 	Compensation of Directors

	 	1.	 	Recommend to the Board approval of the Director’s Compensation Policy.

	 	2.	 	Examine the compensation of Directors in relation to the risks and
duties of their position.

	 	D.	 	Stock Option Grants

	 	1.	 	Oversee, review as needed and recommend Board approval of the Company
Share Option Plan.

	 	2.	 	The Committee may delegate, at its discretion, the plan’s
administration to members of the Company’s Management and employees.

	 	3.	 	Examine, oversee and recommend Board approval of stock option grants,
specifically:

	 	a.	 	the people to whom options are granted;

	 	b.	 	the number of options granted;

	 	c.	 	the exercise price of the options;

	 	d.	 	the exercise period of the options; and

	 	e.	 	all other conditions relating to options granted.

	 	4.	 	Overall Increase in Total Compensation
	 
	 	 	 	Approve annually the Company’s increase in overall compensation.

III. External Advisors

In discharging its duties and responsibilities, the Committee is empowered to retain external legal
counsel or other external advisors, as appropriate. The Company shall provide the necessary funds
to secure the services of such advisors.

IV. Composition of the Committee

The Committee is composed of any number of Directors, but no less than three, as may be determined
by the Board from time to time by resolution. Each member of the Committee shall be independent
from the Company, as determined by the Board, in accordance with applicable laws, rules and
regulations.

			
	 	 	 
	Appendix B — Compensation Committee Charter
	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

V. Term of the Mandate

Committee members are appointed by Board resolution to carry out their mandate extending from the
date of the appointment to the next annual general meeting of shareholders, or until successors are
so appointed.

VI. Vacancy

The Board may fill vacancies at any time by resolution. Subject to the constitution of the quorum,
the Committee’s members can continue to act even if there is one or many vacancies on the
Committee.

VII. Chairman

The Board appoints the Committee Chairman who will call and chair the meetings.

VIII. Secretary

Unless decided otherwise by resolution of the Board, the Secretary of the Company shall act as
Committee Secretary. The Secretary must attend Committee meetings and prepare the minutes. He/she
must provide notification of meetings as directed by the Committee Chairman. The Secretary is the
guardian of the Committee’s records, books and archives.

IX. Meeting Proceedings

The Committee establishes its own procedures as to how meetings are called and conducted. Unless
it is otherwise decided, the Committee shall meet privately and independently from Management at
each regularly scheduled meeting. In the absence of the regularly appointed Chairman, the meeting
shall be chaired by another Committee member selected among attending participants and appointed
accordingly. In the absence of the regularly appointed Secretary, Committee members shall designate
someone to carry out this duty.

X. Quorum and Vote

Unless the Board otherwise specifies by resolution, two Committee members shall constitute an
appropriate quorum for deliberation of items on the agenda. During meetings, decisions are reached
by a majority of votes from Committee members, unless the quorum is of two members, in which case
decisions are made by consensus of opinion.

XI. Records

The Committee keeps records that are deemed necessary for its deliberations and reports to the
Board on its activities and recommendations on a regular basis.

XII. Effective Date

This charter was adopted by the Directors at its May 3, 2004 Board meeting. It was amended by the
Directors during the February 8, 2006 Board meeting.

			
	 	 	 
	Appendix B — Compensation Committee Charter
	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

APPENDIX C

MANDATE OF THE BOARD OF DIRECTORS

I. Role

The Company’s Board of Directors (the “Board”) is ultimately responsible for the stewardship of the
Company and executes its mandate directly or after considering recommendations from its related
committees and Management.

Management is responsible for the Company’s day-to-day activities and is charged with realizing
strategic activities approved by the Board within the scope of its authorized business activities,
capitalization plan and company directives. Management must report regularly to the Board on
matters relating to short-term results and long-term development activities.

II. Obligations and Responsibilities

The Board carries out the functions, performs duties and assumes the responsibilities entrusted by
the laws and regulations. The Board may delegate some of its responsibilities to Board committees
and Management within the scope of the Company’s General By-laws, the laws and the regulations.
Therefore, day-to-day management of the Company’s activities is entrusted to Senior Management,
which reports directly to the Board. One of the key functions of the Board is to appoint the
senior management team.

The functions and duties of Board members include, without limitation, the following functions and
duties:

	 	A.	 	Appointment, assessment, succession planning of Senior Management

	 	1.	 	Select and appoint the President and Chief Executive Officer of the
Company.
	 
	 	2.	 	Oversee the appointment of other members of Senior Management.
	 
	 	3.	 	Ensure that the Company has a succession plan for the President and
Chief Executive Officer.
	 
	 	4.	 	Monitor the performance of the President and Chief Executive Officer
and others Executive Officers, with respect to pre-established objectives.

	 	B.	 	Compensation of Directors

	 	1.	 	Establish the compensation of Directors.

	 	C.	 	Strategic Direction and Planning

	 	1.	 	Adopt the Company’s strategic planning process.
	 
	 	2.	 	Approve the Company’s strategic plan and review Senior Management’s
performance in implementing the plan.

			
	 	 	 
	Appendix C — Mandate of the Board of Directors	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	 	3.	 	Review the strategic plan annually, taking into account opportunities
and risks, and monitoring the Company’s performance against the plan.
	 
	 	4.	 	Review and approve the Company’s annual plans towards financing the
strategic plan.
	 
	 	5.	 	Review and approve the Company’s annual operating budget.
	 
	 	6.	 	Identify key business risks facing the Company and the implementation
of appropriate systems to manage these risks.
	 
	 	7.	 	Discuss with Management how the strategic environment is changing and
the key strategic issues.

	 	D.	 	Corporate Behaviour and Governance

	 	1.	 	Develop an approach to corporate governance, including the
determination of principles and guidelines for the Company.
	 
	 	2.	 	Obtain reasonable assurance of the integrity of the President and Chief
Executive Officer and other senior members of Management, and that they uphold
principles of integrity within the ranks of the Company.
	 
	 	3.	 	Oversee the implementation of a Company disclosure policies and
procedures.
	 
	 	4.	 	Monitor the integrity of the Company’s internal controls and disclosure
systems.
	 
	 	5.	 	Be available to receive feedback from stakeholders, which must be
provided in writing, at the Company’s head office, bearing the mention
“Confidendial”.

	 	E.	 	Personal Behaviours

	 	1.	 	Keep up-to-date with the regular programs and employees of the Company.
	 
	 	2.	 	Upon request, join a committee and actively participate at its
meetings.
	 
	 	3.	 	Be accessible, at least by telephone, to personnel and other Company
Directors, as required.
	 
	 	4.	 	Keep confidential information discussed during meetings.
	 
	 	5.	 	Attend regular and special Board meetings.
	 
	 	6.	 	Get to know other members of the Board and promote collegial
decision-making.

III. External Advisors

In discharging its duties and responsibilities, the Board is empowered to retain external legal
counsel or other external advisors, as appropriate. The Company shall provide the necessary funds
to secure the services of such advisors.

			
	 	 	 
	Appendix C — Mandate of the Board of Directors	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

IV. Composition of the Board

The Board consists of such number of Directors as the Board may determine from time to time by
resolution. The Board must assure itself that it is composed of Directors that are sufficiently
familiar with the business of the Company, and the risks it faces, to ensure active and effective
participation in the deliberations of the Board. Directors should have diverse backgrounds and
personal characteristics and traits as well as competencies and expertise that add value to the
Company. Finally, a majority of the Directors must be independent for the purposes of National
Policy 58-201 Corporate Governance Guidelines.

V. Board Meeting Procedures

The Board follows the procedure established in the Company’s General By-Laws.

VI. Records

The Company’s Secretary keeps the records required by law and any other relevant document.

VII. Effective Date

This written mandate was adopted by the Directors at its February 8, 2006 Board meeting.

			
	 	 	 
	Appendix C — Mandate of the Board of Directors	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

APPENDIX D

DIRECTOR ORIENTATION AND CONTINUING EDUCATION POLICY

The Board must first ensure that every new nominee as Director possesses the necessary skill,
expertise, availability and knowledge to properly fulfil its mandate. Once a Director is
effectively elected, the Chairman of the Board, the President and Chief Executive Officer and
Secretary provide him with the specific information required for a well-informed contribution.

I. Purpose

The purpose of this Director Orientation and Continuing Education Policy (the “Policy”) is to set
forth the Company’s process of orientation for newly appointed Company Directors to familiarize
them with the role of the Company’s Board of Directors, its committees, its directors, and the
nature and operation of the Company’s business activities. The Policy also indicates the elements
of continuing education of the Board of Directors to ensure the Company Directors maintain the
skill and knowledge necessary to fulfill their obligations as directors.

II. Orientation of New Directors

Newly appointed Directors first meet with the Chairman of the Board to discuss the functioning of
the Board of Directors. Then, they meet with the President and Chief Executive Officer to discuss
the nature and operation of the Company’s business activities. As required, meetings may be set up
with other Senior Managers to further clarify some of the Company’s business activities. Finally,
the Secretary provides new directors with the following documents:

	 	A.	 	Copies of Board meeting minutes and written resolutions since the beginning of
the fiscal year (which may include those of the preceding fiscal year, depending of the
date of appointment), including a copy of the minutes of the last annual meeting;
	 
	 	B.	 	A schedule of Board Meetings for the year;
	 
	 	C.	 	The disclosure policies et procedures and the “Undertaking” form (for
signature);
	 
	 	D.	 	The policy on insider trading in force at Theratechnologies (with mention to
register as an insider with the Canadian securities agency through SEDI.ca and to
prepare an initial insider report within ten (10) days following appointment);
	 
	 	E.	 	Theratechnologies’ Share Option Plan;
	 
	 	F.	 	The latest annual report and accompanying information on Theratechnologies
(fact sheet, latest press releases, latest annual information form and corporate
presentation);
	 
	 	G.	 	The Director Disclosure Form (to complete and return within afforded time);
	 
	 	H.	 	The General By-Laws, the Board’s written mandate, the Audit Committee Charter,
Compensation Committee Charter, Nominating and Corporate Governance Charter; and
	 
	 	I.	 	The Directors and Senior Management coverage and compensation.

			
	 	 	 
	Appendix D — Director Orientation and Continuing Education Policy	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

III. Continuing Education

The following actions are taken to ensure the continuing education of Directors:

	 	A.	 	Management provides Directors, from time to time, with pertinent articles and
books relating to the Company’s business, its competitors, corporate governance and
regulatory issues;
	 
	 	B.	 	Key Company executives make regular presentations to the Board on business
activities;
	 
	 	C.	 	Certain consultants present to the Board on matters relevant to their role and
duties. Consultants such as insurance brokers presenting on risks faced by the Company
or consultants presenting a long-term strategy for the Company;
	 
	 	D.	 	The Secretary offers Directors continuing education in the form of
presentations on new legal and regulatory requirements that impact the Board.

IV. Review

This Policy is reviewed and modified when the Board of Directors considers it necessary and
desirable.

			
	 	 	 
	Appendix D — Director Orientation and Continuing Education Policy	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

APPENDIX E

NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER

I. Mandate

The Nominating and Corporate Governance Committee (the “Committee”) is responsible for assisting
the Company’s Board of Directors (the “Board”) in overseeing the following:

	 	A.	 	Recruit candidates for the Board;
	 
	 	B.	 	Review the size of the Board;
	 
	 	C.	 	Composition of the Board;
	 
	 	D.	 	Function of the Board;
	 
	 	E.	 	Orientation and education of Board members; and
	 
	 	F.	 	Governance.

II. Obligations and Duties

The Committee carries out the duties usually entrusted to a Nominating and Corporate Governance
Committee and any other duty assigned from time to time by the Board. Specifically, the Committee
is charged with the following obligations and duties:

	 	A.	 	Recruit Candidates for the Board

	 	1.	 	Identify potential candidates as members of the Company’s Board of
Directors. In so doing, the Committee will consider:

	 	a.	 	independence of candidates under the terms of National Policy
58-201 on corporate governance;
	 
	 	b.	 	the competencies, skills and personal characteristics sought in
candidates. The Committee will determine what it considers necessary by
assessing competencies, skills and personal characteristics of the
candidates in relation to: (1) those generally required by the Board;
(2) those already present in other Board members; and (3) those which
are a welcome addition; and
	 
	 	c.	 	the availability of candidates.

	 	2.	 	All Board members may submit to the Committee potential candidates for
membership, and the Committee shall review such candidates in light of above
described competencies and skills desirable for the Board.
	 
	 	3.	 	The Committee shall proceed as follows for the recruitment of
candidates:

			
	 	 	 
	Appendix E— Nominating and Corporate Governance Committee Charter	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	 	a.	 	as it is determined by the Committee and the Board of Directors
that Board vacancies must be filled or new members are desirable, the
Chairman of the Board of Directors shall make contact with candidates
that have been identified by the Committee per the above described
criteria;
	 
	 	b.	 	upon a positive evaluation by the Chairman of the Board of
Directors and positive reaction from the candidate, at least two (2)
members of the Board shall meet with the candidate; and
	 
	 	c.	 	upon a positive evaluation by the two (2) Board members and the
continuing interest of the candidate, the Committee shall make a
recommendation to the Board of Directors, providing all pertinent
background information for analysis and discussion by the Directors.

	 	B.	 	Board Size
	 
	 	 	 	The Board must be composed of 3 to 20 directors, as per the Company’s articles of
incorporation and by law. As provided under the terms of the Company General
By-Laws, the Board shall exercise its power to establish by resolution the exact
number of directors. In this regard, the duties of the Committee are as follows:

	 	1.	 	Examine the size of the Board annually in view of assessing its
effectiveness.
	 
	 	2.	 	Consider modifications to the number of constituting members and issue
its recommendations to the Board.

	 	C.	 	Composition of the Board

	 	1.	 	Ensure that the Board is composed of Directors that are sufficiently
familiar with the business of the Company, and the risks it faces, to ensure
active and effective participation in the deliberations of the Board.
	 
	 	2.	 	Ensure that Directors have diverse backgrounds and personal
characteristics and traits as well as competencies and expertise that add value
to the Company.
	 
	 	3.	 	Ensure that a majority of the directors are independent directors for
the purposes of National Policy 58-201 Corporate Governance Guidelines.

	 	D.	 	Board Functioning

	 	1.	 	Examine the Board’s functions and issue recommendations as to its
obligations and role. Among others, the Committee must regularly review the
Board’s written mandate.
	 
	 	2.	 	Determine and review, as needed, the roles and mandates of Board
committees and issue recommendations.

	 	E.	 	Orientation and Continuing Education of Board Members
	 
	 	 	 	Develop an orientation and continuing education policy for Directors.

			
	 	 	 
	Appendix E— Nominating and Corporate Governance Committee Charter	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

	 	F.	 	Governance

	 	1.	 	Follow corporate governance developments and, as required, advise the
Board of appropriate actions.
	 
	 	2.	 	Examine appropriate actions to promote ethical business conduct, issue
relevant recommendations to the Board and oversee their implementation.
	 
	 	3.	 	Examine conflict of interest issues that may be brought to the
attention of the Board and offer solutions.

III. External Advisors

In discharging its duties and responsibilities, the Committee is empowered to retain external legal
counsel or other external advisors, as appropriate. The Company shall provide the necessary funds
to secure the services of such advisors.

IV. Composition of the Committee

The Committee is composed of any number of Directors, but no less than three, as may be determined
by the Board from time to time by resolution. Each member of the Committee shall be independent
from the Company, as determined by the Board in accordance with applicable laws, rules and
regulations.

V. Term of the Mandate

Committee members are appointed by Board resolution to carry out their mandate extending from the
date of the appointment to the next Annual General Meeting of Shareholders, or until successors are
so appointed.

VI. Vacancy

The Board may fill vacancies at any time by resolution. Subject to the constitution of the quorum,
the Committee’s members can continue to act even if there is one or many vacancies on the
Committee.

VII. Chairman

The Board appoints the Committee Chairman who will call and chair the meetings.

VIII. Secretary

Unless decided otherwise by resolution of the Board, the Secretary of the Company shall act as
Committee Secretary. The Secretary must attend Committee meetings and prepare the minutes. He
must provide notification of meetings as directed by the Committee Chairman. The Secretary is the
guardian of the Committee’s records, books and archives.

IX. Meeting Proceedings

The Committee establishes its own procedures as to how meetings are called and conducted. Unless it
is otherwise decided, the Committee shall meet privately and independently from Management at each
regularly scheduled meeting. In the absence of the regularly appointed Chairman, the meeting shall
be chaired by another Committee member selected among attending participants and appointed
accordingly.

			
	 	 	 
	Appendix E— Nominating and Corporate Governance Committee Charter	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.

 

 

In the absence of the regularly appointed Secretary, Committee members shall designate someone to
carry out this duty.

X. Quorum and Vote

Unless the Board otherwise specifies by resolution, two Committee members shall constitute an
appropriate quorum for deliberation of items on the agenda. During meetings, decisions are reached
by a majority of votes from Committee members, unless the quorum is of two members, in which case
decisions are made by consensus of opinion.

XI. Records

The Committee keeps records that are deemed necessary for its deliberations and reports to the
Board on its activities and recommendations on a regular basis.

XII. Effective Date

This charter was adopted by the Directors during the February 8, 2006 Board meeting.

			
	 	 	 
	Appendix E— Nominating and Corporate Governance Committee Charter	 	 
	Management Proxy Circular
	 	Theratechnologies Inc.EX-4.5

Exhibit 4.5

MATERIAL CHANGE REPORT

Regulation 51-102 Respecting Continuous Disclosure Obligations

Form 51-102F3

	1.	 	NAME AND ADDRESS OF COMPANY:
	 
	 	 	THERATECHNOLOGIES INC.

2310 Alfred-Nobel Boulevard

Montreal, Québec

Canada H4S 2B4
	 
	2.	 	DATE OF MATERIAL CHANGE:
	 
	 	 	December 6, 2010
	 
	3.	 	NEWS RELEASE:
	 
	 	 	A news release was issued concerning this material change on December 6, 2010 on
“Marketwire”. A copy of the news release is available at SEDAR website at www.sedar.com.
	 
	4.	 	SUMMARY OF MATERIAL CHANGE:
	 
	 	 	On December 6, 2010, Theratechnologies Inc. (the “Company”) announced the execution of a
distribution and licensing agreement (the “Agreement”) with Sanofi-Aventis (“Sanofi”)
for the commercialization rights to EGRIFTATM (tesamorelin for injection) in
Latin America, Africa and the Middle East for the treatment of excess abdominal fat in
HIV-infected patients with lipodystrophy.
	 
	5.	 	FULL DESCRIPTION OF MATERIAL CHANGE:
	 
	 	 	On December 6, 2010, the Company announced the execution of the Agreement with Sanofi
for the commercialization rights to EGRIFTATM (tesamorelin for injection) in
Latin America, Africa and the Middle East for the treatment of excess abdominal fat in
HIV-infected patients with lipodystrophy.
	 
	 	 	Under the terms of the Agreement, the Company will be responsible to supply
EGRIFTATM to Sanofi. Sanofi will buy EGRIFTATM from the Company at
an undisclosed selling price. The Company has kept all future development rights to
EGRIFTATM and will be responsible for conducting additional research and
development for any additional programs. Sanofi will be responsible to conduct all
regulatory activities in the aforementioned territories in connection with
EGRIFTATM for the treatment of excess abdominal fat in HIV-infected patients
with lipodystrophy, including seeking the approval of EGRIFTATM in the
different countries. The Company granted Sanofi an option to commercialize
EGRIFTATM in the aforementioned territories for other uses.
	 
	6.	 	RELIANCE ON SUBSECTION 7.1(2) OF REGULATION 51-102:
	 
	 	 	Not applicable.
	 
	7.	 	OMITTED INFORMATION:
	 
	 	 	Not applicable.

 

-2-

	8.	 	SENIOR OFFICER:
	 
	 	 	For further information, contact Jocelyn Lafond, Vice President, Legal Affairs, and
Corporate Secretary of Theratechnologies Inc., at (514) 336-4804, ext. 288.
	 
	9.	 	DATE OF REPORT:
	 
	 	 	December 16, 2010.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]